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A B S T R A C T
Background
Epidemiological evidence has suggested a link between beta2-agonists and increases in asthma mortality. There has been much debate
about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe.
Objectives
The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic
asthma to regular formoterol versus placebo or regular short-acting beta2-agonists.
Search methods
We identified trials using the Cochrane Airways Group Specialised Register of trials. We checked websites of clinical trial registers for
unpublished trial data and Food and Drug Administration (FDA) submissions in relation to formoterol. The date of the most recent
search was January 2012.
Selection criteria
We included controlled, parallel design clinical trials on patients of any age and severity of asthma if they randomised patients to
treatment with regular formoterol and were of at least 12 weeks’ duration. Concomitant use of inhaled corticosteroids was allowed, as
long as this was not part of the randomised treatment regimen.
Data collection and analysis
Two authors independently selected trials for inclusion in the review. One author extracted outcome data and the second author checked
them. We sought unpublished data on mortality and serious adverse events.
Main results
The review includes 22 studies (8032 participants) comparing regular formoterol to placebo and salbutamol. Non-fatal serious adverse
event data could be obtained for all participants from published studies comparing formoterol and placebo but only 80% of those
comparing formoterol with salbutamol or terbutaline.
Three deaths occurred on regular formoterol and none on placebo; this difference was not statistically significant. It was not possible
to assess disease-specific mortality in view of the small number of deaths. Non-fatal serious adverse events were significantly increased
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when regular formoterol was compared with placebo (Peto odds ratio (OR) 1.57; 95% CI 1.06 to 2.31). One extra serious adverse
event occurred over 16 weeks for every 149 people treated with regular formoterol (95% CI 66 to 1407 people). The increase was
larger in children than in adults, but the impact of age was not statistically significant. Data submitted to the FDA indicate that the
increase in asthma-related serious adverse events remained significant in patients taking regular formoterol who were also on inhaled
corticosteroids.
No significant increase in fatal or non-fatal serious adverse events was found when regular formoterol was compared with regular
salbutamol or terbutaline.
Authors’ conclusions
In comparison with placebo, we have found an increased risk of serious adverse events with regular formoterol, and this does not appear
to be abolished in patients taking inhaled corticosteroids. The effect on serious adverse events of regular formoterol in children was
greater than the effect in adults, but the difference between age groups was not significant.
Data on all-cause serious adverse events should be more fully reported in journal articles, and not combined with all severities of adverse
events or limited to those events that are thought by the investigator to be drug-related.
P L A I N L A N G U A G E S U M M A R Y
Does daily treatment with formoterol result in more serious adverse events compared to placebo or daily salbutamol?
Asthma is a common condition that affects the airways - the small tubes that carry air in and out of the lungs. When a person with
asthma comes into contact with an irritant (an asthma trigger), the muscles around the walls of the airways tighten, the airways become
narrower, and the lining of the airways becomes inflamed and starts to swell. This leads to the symptoms of asthma - wheezing, coughing
and difficulty in breathing. They can lead to an asthma attack or exacerbation. People can have underlying inflammation in their lungs
and sticky mucus or phlegm may build up, which can further narrow the airways. There is no cure for asthma; however there are
medications that allow most people to control their asthma so they can get on with daily life.
Long-acting beta2-agonists, such as formoterol, work by reversing the narrowing of the airways that occurs during an asthma attack.
These drugs - taken by inhaler - are known to improve lung function, symptoms, quality of life and reduce the number of asthma
attacks. However, there are concerns about the safety of long-acting beta2-agonists, particularly in people who are not taking inhaled
corticosteroids to control the underlying inflammation. We did this review to take a closer look at the safety of people taking formoterol
daily compared to people on placebo or the short acting beta2-agonist salbutamol.
There was no statistically significant difference in the number of people who died during treatment with formoterol compared with
placebo or salbutamol. Because so few people die of asthma, huge trials or observational studies are normally required to detect a
difference in death rates from asthma. There were more non-fatal serious adverse events in people taking formoterol compared to those
on placebo; for every 149 people treated with formoterol for 16 weeks, one extra non-fatal event occurred in comparison with placebo.
There was no significant difference in serious adverse events in people on formoterol compared to regular salbutamol.
We conclude that regular formoterol should not be taken by people who are not taking regular inhaled steroids due to the increased
risk of serious adverse events. Formoterol should not be used as a substitute for inhaled corticosteroids, and adherence with inhaled
steroids should be kept under review if separate inhalers are used when formoterol is added to inhaled corticosteroids.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Regular formoterol versus placebo or salbutamol for chronic asthma: SAEs in adults and children
Patient or population: patients with chronic asthma
Settings: community
Intervention: regular formoterol versus placebo or salbutamol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Regular formoterol ver-
sus placebo or salbuta-
mol
SAEs - formoterol versus
placebo
(follow-up: mean 16
weeks)
Medium-risk population OR 1.57
(1.05 to 2.37)
6646
(19)
⊕⊕⊕⊕
high
10 per 1000 16 per 1000
(10 to 23)
SAEs - formoterol versus
salbutamol
(follow-up: mean 13
weeks)
Medium-risk population OR 0.72
(0.37 to 1.43)
2119
(9)
⊕⊕⊕©
moderate1
23 per 1000 17 per 1000
(9 to 33)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio; SAE: serious adverse event
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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B A C K G R O U N D
Description of the condition
There is currently no universally accepted definition of the term
’asthma’. This is in part due to an overlap of asthmatic symptoms
with those of other diseases such as chronic obstructive pulmonary
disease (COPD), but is also due to the probable existence of more
than one underlying pathophysiological process. There are, for
example, wide variations in the age of onset, symptoms, triggers,
associations with allergic disease and the type of inflammatory cell
infiltrate seen in patients diagnosed with severe asthma (Miranda
2004). Patients with all forms and severity of disease will typically
have intermittent symptoms of cough, wheeze and/or breathless-
ness. Underlying these symptoms there is a process of variable, at
least partially reversible airway obstruction, airway hyper respon-
siveness and, in most cases, chronic inflammation.
Airway obstruction
Patients with a history of asthma demonstrate chronic changes
within the airways including goblet cell hyperplasia, airway
smooth muscle (ASM) hyperplasia and hypertrophy (Ebina 1993;
Ordonez 2001; Woodruff 2004) and excess myofibroblasts with
increased subepithelial collagen deposition (Brewster 1990). In
the acute setting, in patients who have died of status asthmati-
cus, airway obstruction is evident from air-trapping and lung hy-
perinflation with mucus plugging of the small and large airways
(Dunnill 1960; Kuyper 2003). There is also shedding of ciliated
bronchial mucosal cells, inflammatory cell infiltrates and submu-
cosal oedema with transudation of fluid into the bronchial lu-
men (Carroll 1993). It is more difficult to measure the degree of
ASM contraction (bronchoconstriction) in post-mortem studies
although evidence for a role of bronchoconstriction in airway nar-
rowing comes from other sources.
Airway hyper responsiveness
Patients with asthma typically display a degree of ’airway hy-
per responsiveness’ to inhaled allergens (Cockcroft 2006), and
to a variety of chemical stimuli including histamine, serotonin,
bradykinin, prostaglandins, methacholine and acetylcholine as
well as other triggers such as exercise, deep inhalation and in-
halation of cold air (Boushey 1980). Bronchoconstriction is im-
plicated as the primary effector mechanism of airway narrowing
in these responses. This is because of both the short time frame
of the response and because many of these stimuli typically ei-
ther cause bronchoconstriction directly in vitro or promote bron-
choconstriction through interference with the autonomic control
of ASM. Further evidence comes from findings that this response
can be abolished or diminished by bronchodilator medications
such as atropine and beta2-agonists (Phillips 1990; Simonsson
1967); although beta2-agonists in particular may have additional
mechanisms of action. Whether airway hyper responsiveness re-
lates primarily to an abnormality of ASM, to increased ASM bulk
(Wiggs 1990), to aberrant autonomic control or reflex pathways,
or to physical damage to the airway epithelium remains to be es-
tablished. Regular use of salbutamol has, however, been shown
to increase airway hyper responsiveness to allergen exposure and
produce tolerance to the protective effect of salbutamol against
bronchoconstriction induced by both methacholine and allergens
(Cockcroft 1993).
Inflammation
It has long been thought that the histological changes described
above and the phenomenon of airway hyper responsiveness are
due to a combined acute and chronic inflammatory response
(Bousquet 2000). Patients with status asthmaticus have increased
numbers of inflammatory cells including eosinophils and neu-
trophils, as well as a variety of pro-inflammatory cytokines and
chemokines found in bronchial alveolar lavage (Tonnel 2001). In
patients with chronic asthma there is also evidence of increased
eosinophil numbers (Bousquet 1990), inflammatory cell adhesion
molecules (Vignola 1993) and some evidence of an association be-
tween the extent of inflammation, disease severity and hyperreac-
tivity. This association has however been questioned on the back-
ground of a number of negative results (Brusasco 1998), although
it is made difficult to prove by the lack of a consistent marker of
a sequential and variable inflammatory response (Haley 1998).
Description of the intervention
Beta2-agonists and mortality: an historical
perspective
Time trend data and case-control studies
Adrenaline was successfully used in the symptomatic treatment
of asthma as far back as 1903 (Tattersfield 2006). Initially given
subcutaneously, the inhaled route was tried in 1929 to reduce ad-
verse effects but these remained a problem and in 1940 details of
a new agent, isoprenaline (isoproterenol), were published in Ger-
many (Konzett 1940). Although isoprenaline was more selective
for beta- as opposed to alpha-adrenoreceptors, adverse effects in-
cluding palpitations were still a major problem, particularly with
oral administration (Gay 1949) and it first became available as
atomiser spray for use in the UK in 1948 (Pearce 2001).
Prior to the 1940s, mortality rates from asthma in a number of
countries were stable and low at less than 1 asthma death per
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100,000 people per year (Pearce 2001; Figure 1).During the 1940s
and 50s there was a slight rise in mortality rates and concerns
about a possible link to inhaled adrenaline were raised at an early
stage (Benson 1948). However, the rise was small and the cause
unclear and sales continued to increase with the introduction of
aerosol or metered-dose inhalers in the early 1960s. During this
decade there was an epidemic of asthma deaths in at least six coun-
tries including England, Wales and New Zealand (Figure 1). In
all six countries the epidemics coincided with the licensing of an
aerosol called ’Isoprenaline Forte’, which contained five times the
dose of isoprenaline per administration than the standard prepara-
tion (Stolley 1972). In other countries including the Netherlands,
where isoprenaline forte was introduced late and sales volumes
low, and in the US, where isoprenaline forte was not licensed, no
increase in asthma mortality occurred. This was despite an ap-
proximate trebling in per capita alternative bronchodilator sales
between 1962 and 1968 in the US (Stolley 1972). A detailed re-
view of the epidemic in England and Wales concluded it was not
due to changes in death certification, disease classification or an
increase in asthma prevalence, but instead was most likely due to
new methods of treatment (Speizer 1968). In England and Wales
mortality rates fell following health warnings about the overuse
of inhalers and banning of over the counter sales in 1968. It was
around this time that more selective beta2-agonists such as terbu-
taline (Bergman 1969) and salbutamol (albuterol) (Cullum 1969)
were being developed.
Figure 1. Changes in asthma mortality (5 to 34 age group) in three countries in relation to the introduction
of isoprenaline forte in the UK and New Zealand and of fenoterol in New Zealand. (From Blauw 1995. With
permission from the Lancet).
In the late 1970s a second epidemic of asthma deaths occurred
in New Zealand (Figure 1). It was later shown that this epidemic
coincided with the introduction and rising sales of fenoterol, a
new short-acting beta2-agonist (Crane 1989; Figure 2). A signifi-
cant association between mortality and fenoterol use was demon-
strated in three consecutive case-control studies, the latter stud-
ies addressing criticisms of the first (Crane 1989; Grainger 1991;
Pearce 1990). Furthermore the relative risk of asthma death in pa-
tients prescribed fenoterol increased markedly when analysis was
restricted to subgroups defined by markers of severity, including
previous hospital admission and use of oral corticosteroids. Fol-
lowing the publication of the first case-control study, the fenoterol
market share in New Zealand fell from 30% in 1988 to 3% in
1991 and by the early 1990s the mortality epidemic appeared to
be over (Figure 2). During the gradual decline in mortality in New
Zealand from its peak in 1979, total sales of alternative beta2-ago-
nists, including salbutamol, gradually rose and the use of inhaled
corticosteroids also increased during the latter half of the 1980s
(Pearce 2007).
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Figure 2. Inhaled fenoterol market share and annual asthma mortality in New Zealand in persons aged 5 to
34
The introduction of long-acting beta2-agonists
Given the relatively short action of beta2-agonists such as salbu-
tamol, in the late 1980s efforts were made to develop longer-
acting compounds. Subsequently the long-acting beta2-agonists
(LABAs), salmeterol and formoterol were released by Glaxo-
SmithKline (GSK) and Novartis, respectively. Both drugs cause
bronchodilation that lasts for more than 12 hours although for-
moterol has a faster onset of action (Kemp 1993; Ringdal 1998).
Given previous concerns about the safety profile of some of the
short acting beta2-agonists, salmeterol and formoterol were sub-
ject to randomised controlled trials on larger numbers of patients.
Using these trials several Cochrane reviews have addressed the effi-
cacy of LABAs in addition to inhaled corticosteroids (Ni Chroinin
2004; Ni Chroinin 2005), in comparison with placebo (Walters
2007), short-acting beta2-agonists (Walters 2002), leukotriene-
receptor antagonists (Ducharme 2006), and increased doses of in-
haled corticosteroids (Greenstone 2005). The beneficial effects of
LABAs on lung function, symptoms, quality of life and exacer-
bations requiring oral steroids have been demonstrated. However,
with some studies demonstrating an associated increase in mor-
tality concerns about the safety profile of LABAs have heightened
and there has been much debate about the potential protective
role of inhaled corticosteroids.
How the intervention might work
We have outlined the pharmacology of beta2-agonists in detail
in Appendix 1. Since the early epidemics in asthma mortality, a
number of potential mechanisms have been proposed to explain a
relationship to the use of beta2-agonists. We discuss these mech-
anisms in detail in Appendix 2; they include direct toxicity, toler-
ance, delay in seeking help and reduction in use of inhaled corti-
costeroids.
Why it is important to do this review
We have taken a different approach from Salpeter 2006, in that we
have not assumed a class effect of long-acting beta2-agonists, but
we have considered trials comparing regular formoterol to placebo
or regular salbutamol/terbutaline. We have chosen not to include
results from trials on salmeterol in this review, as there are known
differences in the pharmacological properties of salmeterol and
formoterol (Ringdal 1998; Van Noord 1996). This review forms
part of a set of reviews on the safety of regular salmeterol and
formoterol that has now been published (Cates 2008; Cates 2009;
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Cates 2009a; Cates 2011). We have also excluded studies which
randomised participants to formoterol and inhaled corticosteroids
for this review, as these are considered in another review (Cates
2009a).
In view of the difficulty in ascertaining the causation of deaths
and serious adverse events (SAEs), we have considered all-cause
fatal and non-fatal SAEs as the main outcomes of this review, with
asthma-related and cardiovascular events as secondary outcomes.
O B J E C T I V E S
To assess the risk of mortality and non-fatal serious adverse events
in trials which randomise patients with chronic asthma to for-
moterol alone
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials (RCTs) of parallel design, with
or without blinding, in which formoterol alone was randomly
assigned to patients with chronic asthma. We excluded studies on
acute asthma and exercise-induced bronchospasm.
Types of participants
We included patients with a clinical diagnosis of asthma of any
age group, unrestricted by disease severity, previous or current
treatment.
Types of interventions
We included trials that randomised patients to receive inhaled
formoterol twice daily for a period of at least 12 weeks, at any
dose and delivered by any device (metered-dose inhalers (MDIs)
with chlorofluorocarbons (CFCs) or hydrofluoroalkane (HFAs),
or dry powder inhalers (DPIs)). We included studies that used
comparison groups with placebo or short-acting beta2-agonists,
and co-interventionwith leukotriene receptor antagonists, inhaled
or oral corticosteroids or theophylline was allowed as long as they
are not part of the randomised intervention. We excluded studies
that randomised patients to formoterol for intermittent use as a
reliever, and studies that compareddifferent doses of formoterol, or
different delivery devices or propellants (with no placebo arm).We
also excluded studies inwhich formoterol was randomised together
with an inhaled steroid (in separate inhalers or a combined inhaler)
from this review; however these are considered in a separate review
(Cates 2009a).
Types of outcome measures
Primary outcomes
1. All-cause mortality
2. All-cause non-fatal serious adverse events
Secondary outcomes
1. Asthma-related mortality
2. Asthma-related non-fatal serious adverse events
3. Respiratory-related mortality
4. Respiratory-related non-fatal serious adverse events
5. Cardiovascular-related mortality
6. Cardiovascular-related non-fatal serious adverse events
7. Asthma-related non-fatal life-threatening events (intubation
or admission to intensive care)
8. Respiratory-related non-fatal life-threatening events
(intubation or admission to intensive care)
We did not restrict outcomes to those that the trial investigators
considered to be related to trial medication.
Search methods for identification of studies
Electronic searches
We identified trials using theCochrane Airways Group Specialised
Register of trials, which is derived from systematic searches of
bibliographic databases including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and handsearching of respira-
tory journals and meeting abstracts (see Appendix 3 for details).
All records in the Specialised Register coded as ’asthma’ were last
searched in January 2012 using the following terms:
(((beta* and agonist*) and (long-acting or “long acting”)) or ((beta*
and adrenergic*) and (long-acting or “long acting”)) or (bron-
chodilat* and (long-acting or “long acting”)) or (salmeterol or for-
moterol or eformoterol or Advair or Symbicort or serevent or Sere-
tide or Oxis)) AND (serious or safety or surveillance or mortality
or death or intubat* or adverse or toxicity or complications or
tolerability)
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references. We also checked websites of clinical
trial registers for unpublished trial data and FDA submissions in
relation to formoterol.
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Data collection and analysis
Selection of studies
Both authors (CJC, MJC) independently assessed studies iden-
tified in the literature searches by examining titles, abstract and
keywords fields. We obtained studies that potentially fulfilled the
inclusion criteria in full text. We independently assessed these full-
text trial reports for inclusion. We resolved disagreements by con-
sensus. We kept a record of decisions.
Data extraction and management
We extracted data using a prepared checklist before entering into
RevMan 5.0. We entered data on characteristics of included stud-
ies (methods, participants, interventions, outcomes) and results
of the included studies. We contacted authors or manufacturers
if serious adverse event data were not included in the trial report,
and searched manufacturers’ and FDA websites for further details
of adverse events.
Assessment of risk of bias in included studies
Both authors assessed the included studies for bias protection (in-
cluding sequence generation for randomisation, allocation con-
cealment, blinding of participants and assessors, loss to follow-
up, completeness of outcome assessment and other possible bias
prevention). We resolved disagreements by consensus.
Measures of treatment effect
We recorded the number of participants with a serious adverse
event of any cause (fatal andnon-fatal), and in view of the difficulty
in deciding whether events are asthma-related, we noted details
of the cause of death and serious adverse events where they were
available. We noted the definition of serious adverse events, and
sought further information if this was not clear (particularly in
relation to hospital admissions and serious adverse events).
Unit of analysis issues
We extracted data using the number of participants who suffered
one or more serious adverse events, in order to avoid double-
counting events from the same participant.
Assessment of heterogeneity
We assessed heterogeneity in the pooled odds ratio using the I2
statistic in RevMan 5.0.
Assessment of reporting biases
We assessed reporting bias by comparing the published and un-
published serious adverse events, and by comparing all serious ad-
verse events with those that were thought to be drug-related. We
also compared serious events with all adverse events (whether se-
rious or not).
Data synthesis
The outcomes of this review were dichotomous and we recorded
the number of participants with each outcome event, by allocated
treated group. We planned to analyse mortality using risk differ-
ence, as many studies did not have any deaths in either arm. How-
ever, the recently revised Cochrane Handbook for Systematic Re-
views of Interventions advises against this approach, so we only used
the risk differences to estimate the absolute impact of treatment
(Higgins 2008). Although meta-analysis with Peto odds ratio has
advantages when events are rare (Bradburn 2007), it performs less
well with unbalanced treatment arms and large effect sizes, and
therefore we calculated the results for serious adverse events and
mortality in RevMan 5.0 as pooled odds ratios using the Mantel-
Haenszel (MH) fixed-effect model. We compared the results of
this model to the Peto method and MH random-effects models
(as sensitivity analysis), although Bradburn 2007 cautions against
the random-effects model as the variance calculations are based
on large sample assumptions. We explored heterogeneity on the
basis of the subgroup and sensitivity analyses outlined below. We
inspected funnel plots to assess publication bias.
Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses on the primary outcomes on
the basis of dose of formoterol (usual dose versus high dose), age
(adults versus children) and comparator used.We planned to carry
out subgroup analysis based on reported corticosteroid use, but
none of the studies reported whether the patients who actually
suffered serious adverse events were taking inhaled corticosteroids
or not.We compared subgroups using tests for interaction (Altman
2003).
The definition of serious adverse events was rarely reported in the
trials, but there is a standard definition used by industry in clinical
study reports (ICHE2a 1995) and this is listed in Appendix 4.
Sensitivity analysis
We checked the overall results for the primary outcomes to assess
the impact of removing the results fromunblinded studies, and also
those participants that were randomised to high-dose formoterol
(24 µg twice daily). We also checked the impact of using fixed or
random-effects models for meta-analysis.
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R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
See Figure 3 for the study flow diagram. We found 512 abstracts
from the initial search in October 2007 (reduced to 504 after re-
moving duplicates). We identified 128 relevant abstracts that re-
lated to formoterol alone. We included 22 studies (32 references)
in the review and excluded 95 others (see Excluded studies). Of
those excluded 53 were less than 12 weeks in duration, (including
29 single-dose studies), three were not RCTs, eight were dose or
device comparison studies, nine were on exercise-induced bron-
chospasm or acute asthma, nine used formoterol as reliever med-
ication, eight were cross-over in design, three randomised to for-
moterol and budesonide and five were excluded for other reasons.
One study that was included in Salpeter 2006 was excluded from
this review because formoterol was randomised with budesonide
(Price 2002) and therefore did not fit the inclusion criteria for this
review. Both authors reached consensus on all the included studies
after inspection of the full text from papers and websites.
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Figure 3. Study flow diagram.
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We repeated the search in July 2008, when we found 48 further
abstracts. Six were relevant to this review but we excluded five
as they were short-term studies, and one was on exercise-induced
bronchospasm; we found no new studies meeting the inclusion
criteria. Similarly a further search in January 2012 (cumulative
total of 748 citations) identified three potentially relevant studies
(Happonen 2009; Kamenov 2007; Price 2008). On checking the
full text, none of these yielded new trials that were suitable for
inclusion (see Excluded studies).
We identified one additional included study from other reviews;
this was a trial on the AstraZeneca controlled trials register
(SD-037-0344) which is otherwise unpublished. Additionally two
documents on the FDA website provided additional serious ad-
verse event information for four of the included studies (Bensch
2001; Bensch 2002; Pleskow 2003; Wolfe 2006). Additionally 22
studies of at least four weeks duration are listed in the appendix
to a Novartis FDA submission (NovartisNDA20-831 2005), but
it is not clear how these relate to the 10 included studies that we
found which were supported by Novartis.
Included studies
We included 22 studies on 8032 participants (6693 adults and
1339 children); the characteristics of these studies are fully de-
scribed in Characteristics of included studies. Sponsorship of the
studies is also listed in Table 1.
Eight studies enrolled adults over 18 years of age (Ekstrom 1998;
Ekstrom 1998a; FitzGerald 1999; Hekking 1990; Kesten 1991;
Molimard 2001; Steffensen1995; van derMolen 1997), one study
adults over 16 years of age (van Schayck 2002), eight studies adults
and adolescents over 12 years of age (Bensch 2001; Busse 2004;
Corren 2007; LaForce 2005; Noonan 2006; Pleskow 2003; SD-
037-0344; Wolfe 2006) and five enrolled children from five up to
12 or 16 years of age (Bensch 2002; Kozlik-Feldmann 1996; Levy
2005; Von Berg 2003; Zimmerman 2004).
All of the studies were of 12 weeks duration with the exception
of Bensch 2002 (52 weeks), FitzGerald 1999 (24 weeks), van der
Molen 1997 (24 weeks) and Wolfe 2006 (16 weeks). This gives
a weighted mean duration of 16 weeks for the 19 studies with a
placebo arm.
Since many of the studies randomised patients to more than two
treatment arms, we have reported the overall number of patients
randomised to treatment categories under investigation. Adults
and adolescents are combined, as separate data for adolescents
were not provided in any of the studies. In total 8032 participants
were randomised (6693 adults and 1339 children); of these 2146
adults and 483 children received placebo, 2483 adults and 568
children received formoterol up to 12 µg twice daily, 921 adults
and 277 children received formoterol 24 µg twice daily, and 1143
adults and 11 children received regular salbutamol or terbutaline.
Although Molimard 2001 was an open study that did not use a
placebo group, we included it in the placebo comparisons as on-
demand salbutamol was used by patients in both the formoterol
and the comparison arm.
Doses of formoterol ranged from 4.5 µg to 24 µg twice daily in
children and 6 µg to 24 µg twice daily in adults (but different
delivery devices mean that the delivered dose may not be identical
between studies, even if the nominal dose is the same). We have
considered high-dose formoterol to be 24 µg twice daily.
Concurrent use of inhaled corticosteroids varied in the included
studies from zero to 100%; Table 2 lists the inhaled steroid use
by study. In almost all the studies at least half of the patients were
taking inhaled corticosteroids at baseline.
Risk of bias in included studies
Figure 4 show a graphical representation of the domains of risk of
bias across each study.
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Figure 4. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Allocation concealment and sequence generation were often
poorly reported in the included studies. However, the majority
of the studies are supported by manufacturers of formoterol (see
Table 1) and are therefore likely to have had appropriate protec-
tion against selection bias.
Blinding
All studies were double-blind except for Kozlik-Feldmann 1996,
Molimard 2001 and van Schayck 2002, and of these only
Molimard 2001 has contributed data to the primary outcomes.
Incomplete outcome data
The included studies generally had withdrawal rates of less than
20% with the exception of Corren 2007 (51% dropout in the
placebo group), and Noonan 2006 (60% withdrawals in placebo
arm and 51.2% in formoterol arm).
Selective reporting
Although paper reports of studies often did not include usable in-
formationon all-cause serious adverse events, it has provedpossible
to obtain serious adverse events information from 19 of the 22 in-
cluded studies. This represents 100% of participants randomised
to formoterol or placebo, but only 80% of participants compared
to regular salbutamol or terbutaline. There are clear guidelines for
the reporting of serious adverse events for industry (ICHE3 2007).
These all have to be listed in detail for the regulatory authorities,
but there is clearly no similar expectation from medical journals.
Twenty-two studies of at least four weeks duration are listed in the
appendix to a Novartis FDA submission (NovartisNDA20-831
2005), but it is not clear howmany of these would fulfil the criteria
for inclusion in this review, or how they related to the 10 Novartis
studies included in this review (Table 1). It has not been possible
to obtain further information from the sponsors.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings - SAE all ages; Summary of findings 2 Summary of
findings - mortality (all-cause); Summary of findings 3 Summary
of findings - SAE children
Primary outcomes
All-cause mortality
Events were sparse in the trials and the presence or absence of
mortality was not always reported in the paper publications.
Formoterol versus placebo
Data were available from 14 studies comparing formoterol (N
= 3413) with placebo (N = 2050); this represents 80% of the
randomised patients for this comparison. Three deaths occurred
in these trials (two adults and one child), and overall there were
three deaths on formoterol and none on placebo. The cause of
death for one adult was not reported in SD-037-0344, there was
one adult death from asthma in Pleskow 2003, and one child died
of a subarachnoid haemorrhage in Von Berg 2003. The pooled
odds ratio (OR) was not statistically significant (Peto OR 4.50;
95% confidence interval (CI) 0.41 to 49.49), see Figure 5. The
confidence interval and point estimate are somewhat different for
a Mantel-Haenszel OR 1.52 (95% CI 0.24 to 9.71) using fixed or
random-effects models. This discrepancy is due to the continuity
correction required for zero cells in the Mantel-Haenszel method.
The point estimate of the pooled risk difference (RD) was an
increase of 4 deaths per 10,000 treated with regular formoterol
over 16 weeks, with a confidence interval from 20 fewer deaths to
28 more deaths per 10,000. There was no statistical heterogeneity
in this outcome.
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Figure 5. Forest plot of comparison: 1 All-cause mortality, outcome: 1.1 Overall results.
Formoterol versus salbutamol
Data were available from six studies comparing formoterol (N =
847) to salbutamol/albuterol (N = 571), representing 49% of the
randomised patients for this comparison. Only two deaths oc-
curred, both in Pleskow 2003; one in the formoterol arm (from
asthma as reported above) and one in the salbutamol arm (from
pancreatitis), and again the difference was not statistically signifi-
cant. As only one study contributed to this outcome, we calculated
no pooled OR.
Subgroup analyses
No subgroup analyses were possible for all-cause mortality as the
data were too sparse.
Serious adverse events (SAEs) (non-fatal all-cause)
An example of the definition of a serious adverse event (SAE)
is given in Pleskow 2003: “A serious adverse event was defined
as any experience that was fatal or life-threatening, permanently
disabling, requiring in-patient or prolonged hospitalisation, or was
a congenital abnormality, cancer or drug overdose.” This is in line
with the definition in Appendix 4, and we have assumed that this
definition was used in the other trials (even though this was often
not made explicit). In most cases the events were defined as serious
because they were associated with hospital admission.
Formoterol versus placebo
Combined data from adults and children
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Data were available on non-fatal SAEs for 19 studies comparing
regular formoterol (N = 4017) to placebo (N = 2629); this rep-
resents all of the randomised patients from published studies for
this comparison. The studies were largely on adults (N = 5311),
but five trials were in children (N = 1335).
The overall result indicated an increased risk of SAEs with for-
moterol (Peto OR 1.57; 95% CI 1.06 to 2.31) with low hetero-
geneity (I2 = 0%), Figure 6. SAEs were rare in the studies (occur-
ring in 1.2% of patients on placebo over a weighted mean of 16
weeks), so the pooled risk difference is small at 0.007 (95% CI
0.0012 to 0.013) and using a weighted mean of the placebo arms,
over a 16-week period there would need to be 149 patients treated
(95% CI 66 to 1407) for one extra serious adverse event to occur;
this number needed to treat was calculated by Visual Rx using
the pooled odds ratio and baseline risk of 1%. This is illustrated
in Figure 7 which shows that for every thousand patients treated
over 16 weeks with formoterol there are an extra six patients who
will suffer a serious adverse event, so that in comparison to 10 per
thousand in the placebo group this rises to 16 per thousand on
regular formoterol.
Figure 6. Forest plot of comparison: 2 Adults and children non-fatal serious adverse events, outcome: 2.1
Formoterol versus placebo or salbutamol.
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Figure 7. Serious adverse events with regular formoterol compared to placebo. In the control group 12
people out of 1000 had serious adverse events over 16 weeks, compared to 19 (95% CI 13 to 27) out of 1000 for
the active treatment group.
Sensitivity analysis by applying theMantel-Haenszel method gave
a very similar result, OR 1.57 (95% CI 1.05 to 2.37). Using a
random-effects model (which is not recommended for rare events
due to an increased risk of bias (Bradburn 2007)), the point es-
timate was similar but the confidence interval widened: OR 1.52
(95% CI 0.96 to 2.40). When we excluded the participants re-
ceiving high-dose formoterol (24 µg) arms from the analysis the
confidence interval again widened (Peto OR 1.55; 95% CI 0.97
to 2.48)(Analysis 3.1).
Adults with non-fatal serious adverse events
When the adult data comparing regular formoterol (N = 3170)
with placebo (N = 2137) were considered on their own, the results
showed a smaller increase in risk which did not reach statistical
significance (Peto OR 1.23; 95% CI 0.76 to 1.99)(Analysis 4.1).
The Mantel-Haenszel method gave very similar results, OR 1.22
(95% CI 0.76 to 1.96).
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Children with non-fatal serious adverse events
Although fewer children were studied, regular formoterol (N =
843) compared with placebo (N = 492), the separate results for
children showed a larger increase in serious adverse events with
regular formoterol (Peto OR 2.48; 95% CI 1.27 to 4.83)(Analysis
5.1). Again theMantel-Haenszel method gave a very similar result,
OR 2.92 (95% CI 1.26 to 6.74). There was low heterogeneity
in this outcome (I2 = 0%), and the result in children remained
significant when the data on high-dose formoterol were excluded
(Peto OR 2.52; 95% CI 1.15 to 5.51) and Mantel-Haenszel OR
2.59 (95% CI 1.08 to 6.19)(Analysis 6.1).
When the results in children are compared with adults using a test
for interaction (Altman 2003), the increased risk in children rela-
tive to adults is a relative OR of 2.39 (95% CI 0.91 to 6.27) using
the Mantel-Haenszel odds ratio, which is not statistically signifi-
cant. The results are very similar when the Peto OR is compared
between adults and children (relative OR 2.02; 95% CI 0.89 to
4.59).
High-dose formoterol versus lower doses
When the study armsusing formoterol 24µg twice dailywere com-
pared to those using lower doses (formoterol 12 µg twice daily),
no significant difference was found in adults (Peto OR 1.35; 95%
CI 0.64 to 2.85)(Analysis 7.1). The confidence interval for this
result is too wide to rule out a difference in relation to dose, and
although the three adult studies all used the same dry powder de-
livery device (Aerolizer), there is a high level of heterogeneity be-
tween studies (I2 = 74%), which is unexplained.
Moreover the data from the Novartis database of published and
unpublished placebo-controlled studies of at least four weeks du-
ration has been included for comparison (Novartis 2005); the No-
vartis data show a significantly higher risk of asthma-related seri-
ous adverse events with formoterol 24 µg twice daily in compar-
ison to 12 µg twice daily (Peto OR 2.16; 95% CI 1.13 to 4.11)
and Mantel-Haenszel OR 2.08 (95% CI 1.11 to 3.89).
Formoterol versus salbutamol
Adults with non-fatal serious adverse events
In contrast, the results from nine studies in adults comparing reg-
ular formoterol (N = 1119) to salbutamol (N = 920), representing
80% of the randomised patients for this comparison, showed a
non-significant reduction in the risk of SAEs (Peto OR 0.73; 95%
CI 0.37 to 1.43)(Analysis 4.1). However, when the results from
patients using high-dose formoterol were excluded, there was a sig-
nificant reduction in risk for formoterol in comparison with salbu-
tamol or terbutaline (Peto OR 0.41; 95% CI 0.19 to 0.90) and
Mantel-Haenszel OR 0.40 (95% CI 0.17 to 0.94) (Analysis 3.1).
A test for interaction between the results comparing formoterol
with placebo and salbutamol was not significant; the risk in tri-
als against regular salbutamol compared to those against placebo
using Mantel-Haenszel OR gives a relative OR of 0.46 (95% CI
0.21 to 1.01), whilst for the Peto method the relative OR is 0.59
(95% CI 0.26 to 1.36).
No studies were found comparing regular formoterol to regular
salbutamol or terbutaline in children.
SAEs all-cause (fatal and non-fatal combined)
When fatal and non-fatal SAEs are considered together the find-
ings are very similar to those for the non-fatal events, with a signif-
icant increase in risk with regular formoterol in comparison with
placebo (Peto OR 1.61; 95% CI 1.09 to 2.37) and Mantel-Haen-
szel OR 1.63 (95% CI 1.08 to 2.44), but not in comparison with
regular salbutamol (see Analysis 8.1).
Secondary outcomes
Mortality by cause of death
Asthma mortality and cardiovascular mortality
Only one death related to asthma was reported using formoterol
24 µg in Pleskow 2003, and one death in Von Berg 2003 from
sub-arachnoid haemorrhage on formoterol 9 µg, so there are in-
sufficient data to assess the impact of formoterol on disease-spe-
cific mortality. The third death in SD-037-0344 has no reported
cause.
SAEs related to asthma and the cardiovascular system
When formoterol is compared to placebo, there is a significant
increase in asthma-related serious adverse events on regular for-
moterol (Peto OR 1.99; 95% CI 1.12 to 3.53) and Mantel-Haen-
szel OR 1.90 (95% CI 1.03 to 3.48)(Analysis 11.1). This finding
is also apparent from the Novartis integrated database (Novartis
2005), which is concordant with the results of the 10 Novartis
studies included in the review as shown in Analysis 12.1.
In comparison with regular salbutamol there is a decrease in
asthma-related serious adverse events on regular formoterol but
this is not significant (Peto OR 0.74; 95% CI 0.29 to 1.88) and
Mantel-Haenszel OR 0.72 (95%CI 0.32 to 1.76)(Analysis 11.1).
There is a significant increase in hospital admissions for asthma
when regular formoterol is compared to placebo: Peto OR 3.28;
95% CI 1.65 to 6.52 and Mantel-Haenszel OR 4.28; 95% CI
1.60 to 11.46 (Analysis 13.1). For this outcome we assumed that
all the patients with asthma-related SAE documented in the FDA
submission were admitted to hospital; in Pleskow 2003 this is
clearly stated to be the case for two patients on placebo and five on
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formoterol 24 µg, but is not clearly reported for the single patient
on formoterol 12 µg (Mann 2003). No significant difference was
seen when regular formoterol is compared to regular salbutamol.
Very few events relating to the cardiovascular systemwere reported,
so although the direction of effect is in favour of formoterol the
confidence intervals in comparison to placebo and salbutamol are
very wide (Analysis 14.1).
Impact of inhaled corticosteroids
It has not been possible to assess whether inhaled corticosteroids
have an impact on SAEs with regular formoterol from the in-
cluded studies, as this would require individual patient data re-
lating inhaled corticosteroid usage to those patients who suffered
the events, and these data are not available. However, data are
presented in Novartis 2005 in which patients on inhaled corti-
costeroids are compared with those who are not, for asthma-re-
lated serious adverse events. Although the increased risk is larger
without inhaled corticosteroids (Peto OR 3.22; 95% CI 1.17 to
8.89) and Mantel Haenszel OR 7.31 (95% CI 0.97 to 55.06),
than with inhaled corticosteroids (Peto OR 2.58; 95% CI 1.21 to
5.49) and Mantel-Haenszel OR 3.47 (95% CI 1.21 to 9.97), the
confidence intervals are wide and there is no statistically significant
interaction between the increased risk and use of inhaled corticos-
teroids. Moreover there remains a significant three-fold increase
in odds for patients who were taking inhaled corticosteroids, and
this is maintained when the data on formoterol 24 µg twice daily
are excluded (Peto OR 2.76; 95% CI 1.06 to 7.15) and Mantel-
Haenszel OR 3.11 (95% CI 1.01 to 9.55)(Analysis 15.1).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Regular formoterol versus placebo or salbutamol for chronic asthma
Patient or population: patients with chronic asthma
Settings: community
Intervention: regular formoterol
Comparison: placebo or salbutamol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or salbutamol Regular formoterol
Mortality
(all-cause) - formoterol
versus placebo
(follow-up: mean 16
weeks)
Medium-risk population OR 1.52
(0.24 to 9.71)
5463
(14)
⊕⊕⊕©
moderate1
0 per 1000 0 per 1000
(0 to 0)
Mortality (all-cause) -
formoterol versus salbu-
tamol
(follow-up: mean 13
weeks)
Medium-risk population OR 0.5
(0.03 to 8.05)
1418
(6)
⊕⊕⊕©
moderate1
0 per 1000 0 per 1000
(0 to 0)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.20
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Regular formoterol versus placebo or salbutamol for children with chronic asthma: serious adverse events
Patient or population: patients with chronic asthma (children)
Settings: community
Intervention: regular formoterol versus placebo or salbutamol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Regular formoterol ver-
sus placebo or salbuta-
mol
SAEs - formoterol versus
placebo
(follow-up: mean 23
weeks)
Medium-risk population OR 2.82
(1.16 to 6.83)
1335
(5)
⊕⊕⊕⊕
high
12 per 1000 33 per 1000
(14 to 77)
SAEs - formoterol versus
salbutamol
See comment See comment Not estimable - See comment
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio; SAE: serious adverse event
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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D I S C U S S I O N
Summary of main results
Three deaths occurred on regular formoterol and none on placebo;
this difference was not statistically significant. It was not possible
to assess disease-specific mortality in view of the small number of
deaths.
Non-fatal serious adverse events (SAEs) were significantly in-
creased in comparison with placebo. These events were rare, oc-
curring in 1.0% of patients in the placebo arms over an average of
16 weeks; in comparison 1.6% of those given regular formoterol
suffered a SAE (Figure 7). One additional participant with a SAE
was found to occur for every 149 people treated with regular for-
moterol over 16 weeks, and the play of chance is compatible with
one extra event for every 66 to 1407 given regular formoterol. The
majority of these extra events appear to be asthma-related, and
data from unpublished studies on theNovartis integrated database
of placebo-controlled trials suggest that there may be a significant
increase in the risk of asthma-related SAEs with regular formoterol
even in those patients who were taking inhaled corticosteroids
(Analysis 15.1).
The increased risk is larger in children than in adults, but the dif-
ference between the results in children and adults is not statisti-
cally significant. No significant overall differences were found for
all-cause mortality or non-fatal SAEs in trials comparing regular
formoterol with salbutamol or terbutaline.
Overall completeness and applicability of
evidence
Although large numbers of participants have been treated with
regular formoterol, the rarity of mortality and SAEs means that
there is still considerable uncertainty in relation to the size of the
effects being investigated. There is insufficient evidence to be sure
whether the larger increase in SAEs found in children is signifi-
cantly different from the smaller increase in adults. We have re-
ceived additional information relating to eight studies from au-
thors and manufacturers, but data have not been forthcoming for
three of the included studies. The missing data represent a mod-
erate proportion of the participants who are in trials comparing
formoterol with salbutamol, but they could alter the point esti-
mates and confidence intervals for this comparison. Whilst it has
not been possible to obtain details of unpublishedNovartis studies
submitted to the FDA, the pooled data from the Novartis trials
has been used in this review (but not combined with the included
studies as there is an unknown degree of overlap).
Information from papers published in medical
journals
All-cause non-fatal SAEs were published in the paper reports
of studies for 31 patients on formoterol and seven patients on
placebo; this less than half of the total number of events found
from all sources. Considering only the data from paper reports
there is still a significant increase with regular formoterol (Peto
odds ratio (OR) 2.31; 95% confidence interval (CI) 1.17 to 4.53),
see Analysis 16.1.
Serious and non-serious adverse events
All adverse events are shown in Analysis 17.1, and published ad-
verse events in Analysis 18.1. Both show small increases with reg-
ular formoterol that do not reach statistical significance, which
may be because the larger number of minor adverse events are
not altered by formoterol. Published drug-related adverse events
showed a significant increase as shown in Analysis 19.1.
Drug-related serious adverse events
If the analysis had been confined to SAEs that were thought to be
drug-related, only five of the 136 SAEs would have been included,
and because there is a wide confidence interval around this small
number of events, no significant increase in drug-related SAEs
was found (Peto OR 1.45; 95% CI 0.18 to 11.61) and Mantel-
Haenszel OR 0.90 (95% CI 0.19 to 4.24) (Analysis 20.1).
Quality of the evidence
All the studies were double-blind with the exception of LaForce
2005, Molimard 2001 and van Schayck 2002. Of these, only
Molimard 2001 contributed data to SAEs with regular formoterol
in comparison with placebo, and if themeta-analysis is confined to
the double-blind trials the increase remains significant (Peto OR
1.52; 95% CI 1.02 to 2.25). There are methodological concerns
in relation to data from the Novartis integrated database, as these
are not presented for the individual studies, but where it has been
possible to compare results from the database with the Novartis
studies included in the review the results are very similar (Analysis
12.1).
Agreements and disagreements with other
studies or reviews
The findings of this review are similar to those of our review com-
paring regular salmeterol to placebo and regular salbutamol (Cates
2008). Both reviews show that, in comparison with placebo, there
are significant increases in all-cause SAEs with the use of regular
long-acting beta2-agonists. The size of this increase is comparable
for regular salmeterol (Peto OR 1.15; 95% CI 1.02 to 1.29) and
regular formoterol (Peto OR 1.57; 95% CI 1.06 to 2.31). The
placebo group event rates were different in the two reviews, so it
would be misleading to try to compare the absolute increases in
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risk between salmeterol and formoterol. Similarly, although the
increase in events reached statistical significance in adults (but not
children) for salmeterol, and in children (but not adults) for for-
moterol, these age group differences may be due to the play of
chance, as the test for interaction between age group and treat-
ment effect was not significant in either case (Altman 2003).
The number of participants is too small to assess the impact of
regular formoterol on all-cause or asthma-related mortality, so it
is not possible to compare these results with the increased asthma
mortality found in SMART 2006. However, data submitted by
Novartis to the FDA (Novartis 2005) do indicate a significant
increase in asthma-related serious adverse events, even in patients
taking regular inhaled corticosteroids (Analysis 15.1).
A recent meta-analysis of individual patient data from trials of
all FDA-approved LABAs found a higher risk of serious asthma-
related events in children as compared to adults (McMahon 2011),
which is in keeping with the results of this review. This increased
risk in children persisted in those who were given concomitant
ICS, but not in the trials in which participants were assigned to
ICS as part of their randomised treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In comparison with placebo, we have found an increased risk of
serious adverse events with regular formoterol, and this does not
appear to be abolished in patients taking inhaled corticosteroids.
The effect on serious adverse events of regular formoterol in chil-
dren was greater than the effect in adults, but the difference be-
tween age groups was not significant.
Implications for research
Data on all-cause serious adverse events should be more fully re-
ported in medical journals, and not combined with all adverse
events or limited to those events that are thought by the investi-
gator to be drug-related.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bensch 2001
Methods A randomised, double-blind, double-dummy, placebo-controlled, multicentre parallel-
group study over 12 weeks at 26 trial sites in the USA. 2-week, single-blind, placebo
lead-in period
Participants Population: 541 adolescents and adults (12 to 75) years withmild tomoderate persistent
asthma
Baseline characteristics: mean age 35.5 years. FEV1 66% predicted. Concomitant in-
haled corticosteroids used by 51% of participants.
Inclusion criteria: mild to moderate persistent asthma requiring daily use of an inhaled
B2-selective adrenergic agent (short- or long-acting). FEV1 between 40% and 80% pre-
dicted after an 8-hour period of abstinence from short-acting B2- adrenergic agonist use.
Bronchodilator reversibility at least a 15% increase in FEV1 within 30 minutes after
inhalation of 180 µg of albuterol delivered via MDI. Co-interventions permitted: ICS
51%, slow release theophylline 17%
Exclusion criteria: URTI, hospitalisation/asthma exacerbation < 4 weeks, serious illness
Interventions 1. Formoterol 12/24 µg BD
2. Albuterol 180 µg QDS
3. Placebo QDS
Formoterol delivered by Aerolizer (dry powder) and albuterol by MDI
Outcomes Primary outcome: FEV1 . Safety was evaluated by adverse event reports.
Paper report: “Adverse events, whether or not trial drug related, were reported by 68%
of patients on formoterol 12 mcg, 76% on formoterol 24 mcg, 70% on albuterol and
71% on placebo. No deaths occurred during the study.”
No SAE data reported but the numbers match FDA submission for study 040 (http:
//www.fda.gov/cder/foi/nda/2001/20831 Foradil medr P1.pdf ). This lists all (asthma-
related in brackets) SAEs as: 1 (0) on formoterol 12 µg, 5 (4) on formoterol 24 µg, 2 (2)
on albuterol and 1 (0) on placebo
Notes Supported by Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, double-dummy. Matching
capsules and devices
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Bensch 2001 (Continued)
Incomplete outcome data (attrition bias)
Adverse Events
Unclear risk All patients included in the safety analysis
Selective reporting (reporting bias) Low risk No SAE data in paper publication, but
FDA submission provided SAE informa-
tion
Bensch 2002
Methods A randomised, double-blind, placebo-controlled, multinational, multicentre, paediatric
study over 52 weeks at 42 centres. Initial run-in period of 2 weeks
Participants Population: 518 children (5 to 12) years with persistent asthma on preventer therapy
Baseline characteristics: mean age 9 years. FEV1 71% predicted. At least 69% were
taking ICS, with 26% on sodium cromoglycate and 5% nedocromil sodium.
Inclusion criteria: persistent asthma diagnosed by ATS criteria. Sodium cromoglycate,
nedocromil sodium and/or ICS for at least 4 weeks before entry in the study, but still
required daily use of inhaled salbutamol (albutamol) to control symptoms. Baseline FEV1
ranged from 50% to 85% of predicted and increased by 15% or more within 30 minutes
after inhaling 200 µg salbutamol (180 µg albuterol in the United States) delivered by
a metered-dose inhaler. Co-interventions: 70% on ICS, 30% on cromones (all stable
dosage)
Exclusion criteria: unstable asthma, URTI, OS course or exacerbation asthma within
4 weeks, QT interval on ECG > 0.46 sec
Interventions 1. Formoterol 12 µg or 24 µg BD
2. Placebo BD delivery was Aerolizer
Outcomes Primary outcome: FEV1 (area under curve)
Paper reports: “There were no deaths in this study.” Table 4 in the paper reports SAE
data but not in a way that allows all-cause SAE data to be extracted. Full SAE data found
on FDA website
Notes Supported by Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind
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Bensch 2002 (Continued)
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 407/518 (78%) completed the study
Selective reporting (reporting bias) Low risk All-cause SAE data not extractable from
published paper, but present in FDA web
report
Busse 2004
Methods Randomised, double-blind, double-dummy, placebo-controlled, parallel-group study
over 12 weeks in outpatient clinics at 18US centres. Run-in 2 weeks single-blind placebo
Participants 239 adolescents and adults (13 to 85) years with persistent asthma. (9 patients were aged
less than 18 years old)
Baseline characteristics: mean age 38 years. FEV1 65%predicted. Concomitant inhaled
corticosteroids used by 64% of participants.
Inclusion criteria: persistent asthma, requiring regular or on-demand bronchodilators,
FEV1 % predicted at least 40%, bronchodilator reversibility by either an increase of at
least 15% in FEV1 over baseline or increases of at least 12% and 200 mL in FEV1 over
baseline within 30 minutes of inhaling albuterol 180 to 360 µg (2 to 4 puffs) via pMDI.
Co-interventions permitted: ICS, cromolyn, montelukast, theophyllines, intra nasal ICS
Exclusion criteria: RT infection, use ofOCS, parenteral CS or hospitalisation for asthma
due to exacerbation < 1 month, use of unstable anti-inflammatory regime, corrected
QT interval > 460 ms, current smoker, ex smoker > 10 Pack years, serious medical
condition, pregnancy, lactation, use of oral beta blocker, non-potassium sparing diuretic,
anti-arrhythmic, tricyclic antidepressant, MAOI, NSAIDS
Interventions 1. Formoterol 10µg BD
2. Placebo BD
3. Albuterol 180 µg QDS
Delivery was DPI for formoterol and MDI for albuterol (salbutamol)
Outcomes The primary efficacy variable was the 12-hour AUC of FEV1 after 12 weeks’ treatment
No deaths in the study. Non-fatal SAEs: formoterol 2 (1 asthma exacerbation and 1
basal cell carcinoma). Albuterol 3 (1 eating disorder, 1 renal calculi and 1 pneumonia).
Placebo 0. No events were considered to be related to study medication
Any AE: formoterol 43, albuterol 47 and placebo 48
Notes Funding Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1:1 ratio using computer-generated list of
random numbers
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Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-dummy matched devices
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 209/239 (87%) completed the study; SAE
reported for both those who withdrew and
those who continued in the study
Selective reporting (reporting bias) Low risk Serious adverse events (fatal and non-fatal)
documented in the paper publication
Corren 2007
Methods Randomised, double-blind, double-dummy, multicentre, placebo-controlled study over
12 weeks at 56 US centres from July 2002 to September 2003. Run-in 7 to 21 days in
which usual asthma therapy was withdrawn
Participants Population: 480 adolescents and adults (12 to 78) years withmild tomoderate persistent
asthma. The web report also includes results from a further 31 children aged 6 to 11
years
Baseline characteristics: mean age 36 years. FEV1 75%predicted. Concomitant inhaled
corticosteroids used by 100%of participants at baseline but withdrawn for the formoterol
and placebo arms of this study
Inclusion criteria: mild to moderate persistent asthma for at least 6 months, treated
with inhaled corticosteroids for at least 4 weeks before screening, FEV1 between 60%
and 90% predicted on ICS at screening and between 50% and 85% predicted after
discontinuation of ICS during run-in period. Bronchodilator reversibility of at least
12% and 0.20 L in FEV1 over baseline within 15 to 30 minutes after administration of
albuterol pMDI (2 to 4 inhalations (90 µg per inhalation))
Exclusion criteria: reasons for exclusion from the study included severe asthma (as
judged by the investigator), asthma requiring hospitalisation once or emergency treat-
ment more than once within the 6 months before the study or requiring treatment with
systemic corticosteroids within the 4 weeks before screening, and/or a > 10 pack-year
smoking history at screening. Pregnant or breastfeeding
Interventions 1. Formoterol 9 µg (DPI)
2. Placebo BID (pMDI)
The Symbicort and budesonide arms of this study are not included in this review
Outcomes The co-primary efficacy variables were changes from baseline in morning predose FEV1
and 12-hour mean FEV1 (from serial spirometry) after administration of the morning
dose of study medication
2 serious adverse events in the placebo group (intestinal obstruction, abdominal pain)
reported on the website. One of these presumably occurred in a child under 12 years, as
the paper reports 1 serious adverse event in those aged over 12 years. No cardiac-related
serious adverse events were reported in any group. No deaths occurred in any group
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Corren 2007 (Continued)
(website data)
Notes Study sponsored by AstraZeneca
http://www.astrazenecaclinicaltrials.com/Article/525476.aspx accessed 16 June 2008 for
web data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk By study site, computer-generated alloca-
tion schedule using balanced blocks of 4
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-dummy. Patients received both a
pMDI and DPI containing either active
treatment or placebo of the alternative ac-
tive treatment as appropriate
Incomplete outcome data (attrition bias)
Adverse Events
Unclear risk ITT analysis used for adverse events. High
dropout rate in placebo group (51%)
Selective reporting (reporting bias) Low risk Serious adverse events reported in paper
publication
Ekstrom 1998
Methods A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-
centre, multinational study (Sweden, Norway, Spain, Italy) over 12 weeks at 25 centres.
Run-in: 2 weeks single-blind placebo
Participants Population: 397 adults (18 to 79) with mild to moderate asthma
Baseline characteristics: mean age 47 years. FEV1 62%predicted. Concomitant inhaled
corticosteroids used by 86% of participants
Inclusion criteria: diagnosis asthma by ATS criteria. FEV1 of 40% to 80% predicted,
bronchodilator reversibility by an increase of at least 15% in FEV1 over baseline and at
least 200 ml, measured after inhalation of 0.5 mg terbutaline via Turbuhaler
Exclusion criteria: not reported
Interventions 1. Formoterol 6 µg BD
2. Terbutaline 500 µg QDS
3. Placebo: placebo QDS
Delivery was dry powder device
Outcomes Primary outcome PEF. Adverse events were assessed by asking patients if they had expe-
rienced any health problems or symptoms not usually associated with their asthma
“Asthma aggravation accounted for two serious adverse events in the terbutaline group
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and one serious adverse event in the placebo group.” Manufacturers asked for all-cause
serious adverse event data, and these have been provided as 1 patient on formoterol, 3
patients on terbutaline and 2 patients on placebo
Notes Author affiliation includes Astra Draco
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, double-dummy, matching
devices
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 359/397 (90%) completed the study
Selective reporting (reporting bias) Low risk All-cause SAE data have been provided by
sponsors
Ekstrom 1998a
Methods A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, mul-
ticentre study over 12 weeks at 28 centres in Scandinavia. Run-in 1 week single blind
Participants Population: 343 adults (18 to 82) with moderate stable asthma
Baseline characteristics: mean age 48 years. FEV1 61%predicted. Concomitant inhaled
corticosteroids used by 89% of participants
Inclusion criteria: diagnosis asthma by ATS criteria. FEV1 of 40% to 80% predicted,
bronchodilator reversibility by an increase of at least 15% in FEV1 over baseline 15
minutes after inhalation of 0.5 mg terbutaline sulphate via Turbuhaler
Co-interventions: ICS 89%, cromones 2% - stable doses OS 2 participants
Exclusion criteria: not reported
Interventions 1. Formoterol 12 µg BD
2. Terbutaline 500 µg QDS
3. Placebo QDS
Delivery was dry powder device - Turbuhaler
Outcomes FEV1, PEF, rescue use, asthma symptom score, adverse events, asthma deterioration
Primary outcome PEF. Adverse events were assessed by asking patients if they had expe-
rienced any health problems or symptoms not usually associated with their asthma
No SAE reporting at all in the paper. Manufacturers asked for all-cause serious adverse
42Regular treatment with formoterol for chronic asthma: serious adverse events (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ekstrom 1998a (Continued)
event data: 4 patients with SAE in terbutaline group and 2 on placebo. Of these 3 and
2 were asthma-related
Notes Author affiliation includes Astra Draco
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random order, bal-
anced blocks
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, double-dummy, matching
devices
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 311/343 (90%) completed the study
Selective reporting (reporting bias) Low risk SAE results provided by sponsors
FitzGerald 1999
Methods A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, mul-
ticentre study over 24 weeks at 15 centres in Canada. Run-in 2 weeks single-blind
Participants Population: 271 adults with moderate to severe asthma
Baseline characteristics: mean age 36 years. FEV1 79%predicted. Concomitant inhaled
corticosteroids used by all the participants
Inclusion criteria: diagnosis asthma by ATS criteria. Using ICS at a constant dose of
400 to 1200 mg/day and inhaled SABA for at least 1 month
Bronchodilator reversibility as a 15% or greater increase in FEV1 15 to 30 minutes after
inhalation of a B2-agonist, and increased sensitivity to inhaled methacholine, defined as
a PC20 less than or equal to 8 mg/mL. Rescue albuterol required on 5 out of 7 days of
run-in period
Exclusion criteria: URTI/change in asthma medication/exacerbation of asthma within
2 months. Smoking
Interventions 1. Formoterol 12 µg BD
2. Placebo QDS
3. Albuterol 200 µg QDS
Delivery was dry powder device
Outcomes The primary end point of this trial was the methacholine PC20 at the end of the double-
blind phase (visit 6)
No SAE data published for this study, but unpublished serious adverse event data pro-
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FitzGerald 1999 (Continued)
vided by the authors
“Drug-related adverse events were reported by 15%, 12% and 10% of the formoterol,
regular albuterol and on-demand albuterol patients, respectively.”
Notes Supported by a grant from Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, double-dummy, matching
devices
Incomplete outcome data (attrition bias)
Adverse Events
Low risk
Selective reporting (reporting bias) Low risk NoSAE reporting in paper and noweb data
found, but data provided by the authors
Hekking 1990
Methods Randomised, double-blind, double-dummy, multicentre, parallel-group study of outpa-
tients over 12 weeks in The Netherlands. Washout period of 12 hours for inhaled and
24 hours for oral medication
Participants Population: 301 adults (18 to 70) years with stable-phase asthma
Baseline characteristics: mean age 40 years. FEV1 not reported. Concomitant inhaled
corticosteroids use not reported (but allowed in protocol).
Inclusion criteria: stable-phase asthma, FEV1 % predicted less than 80%, bronchodila-
tor reversibility greater than 15% in FEV1 over baseline
Exclusion criteria: use of theophyllines, oral beta2 agonists or anticholinergics
Interventions 1. Formoterol 12 µg BD
2. Salbutamol 200 µg QDS
Delivery was MDI
Outcomes PEF, rescue use, asthma attacks, efficacy rating
No report in paper in relation to serious adverse events
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, double-dummy
Incomplete outcome data (attrition bias)
Adverse Events
Unclear risk 15 of 150 formoterol patients and 30 of
151 salbutamol patients were withdrawn
Selective reporting (reporting bias) High risk No SAE reporting in the paper
Kesten 1991
Methods A randomised, double-blind, double-dummy, parallel-group, multicentre, multinational
study (Canada, UK), over 12 weeks at 7 centres. Run-in 4 weeks double-blind cross-over
Participants Population: 145 adults (18 to 65) years with stable, symptomatic asthma
Baseline characteristics: mean age not reported.Mean baseline FEV1 for the formoterol
groupwas 2.14L and1.98L for the albuterol group.Concomitant inhaled corticosteroids
used by 62% of participants
Inclusion criteria: diagnosis of asthma requiring daily treatment with an inhaled B2-
agonist. FEV1 % predicted at least 40%, bronchodilator reversibility by an increase of
at least 15% in FEV1 30 minutes after inhalation of 200 µg of albuterol by metered-
dose inhaler. Use of rescue albuterol greater during the placebo treatment period than
during the albuterol treatment period by an average of 2 puffs per day or more. Co-
interventions: none 32%, ICS 62 %, cromones 7%, theophylline 32%
Exclusion criteria: use of OS, exacerbation asthma within 1 month, significant non-
respiratory illnesses and women of childbearing potential
Interventions 1. Formoterol 10 µg BD
2. Albuterol 180 µg QDS
Delivery was MDI
Outcomes FEV1, FVC, FEV 25% to 75%, PEF, rescue use, rate asthma attacks day and night,
adverse events, exacerbations, efficacy rating
No serious adverse event data reported in the paper. No web data found
Notes Supported by Ciba-Geigy (now Novartis)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, double-dummy, matching
inhalers
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 133/145 (91%) completed the study
Selective reporting (reporting bias) High risk No published SAE data
Kozlik-Feldmann 1996
Methods A randomised, parallel-group, single-centre study over 12 weeks in Germany
Participants Population: 22 children with clinically stable asthma
Baseline characteristics: mean age 10 years. Before treatment, all values for FEV1 were
found beyond 100% of that predicted.
Inclusion criteria: mild asthma, requiring no preventive therapy. The patients needed
no further therapy, i.e. with corticosteroids or theophyllines
Exclusion criteria: requiring additional therapy for asthma
Interventions 1. Formoterol 24 µg BD
2. Salbutamol 200 µg QDS
Delivery was not reported
Outcomes FEV1, FVC, histamine provocation, beta-receptor binding sites on mononuclear leuco-
cytes, adverse events
“No side effects due to beta2-agonist therapy were seen”.
Notes No indication of sponsorship for this study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
Adverse Events
High risk Open
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Incomplete outcome data (attrition bias)
Adverse Events
Low risk All patients completed the study
Selective reporting (reporting bias) High risk No serious adverse event data documented
LaForce 2005
Methods Randomised, double-blind, multicentre, parallel-group study over 12 weeks at 22 sites
in the US. Run-in 2 weeks
Participants Population: 265 adolescents and adults (13 to 81) years with persistent asthma
Baseline characteristics: mean age 37 years. FEV1 68%predicted. Concomitant inhaled
corticosteroids used by 67% of participants.
Inclusion criteria: persistent asthma. FEV1 % predicted at least 40%, bronchodilator
reversibility by an increase of at least 15% in FEV1 over baseline within 30 minutes
of inhaling albuterol (180 to 320 µg) (still eligible if the increase in FEV1 was 12% or
greater and at least 0.2 L over baseline)
Exclusion criteria: pregnant/lactating women; smoking history > 10 pack-years; history
of malignancy; RTI or hospitalisation with exacerbation in previous month; treatment
with systemic steroids
Interventions 1. Formoterol 10 µg BID
2. Placebo
3. Salbutamol 180 µg QID
Delivery was DPI (pMDI for salbutamol)
Outcomes The primary efficacy variable was 12-hour AUC of FEV1 after 12 weeks’ treatment.
“There were no deaths in the study. A total of three patients experienced serious adverse
events andwere withdrawn from the study.” Formoterol 1 small cell lung cancer, albuterol
1 increase in heart rate and 1 coronary artery stenosis
Notes Sponsored by Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1:1 using a computer-generated sequence
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, double-dummy
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 235/265 (89%) completed the study
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Selective reporting (reporting bias) Low risk Deaths and serious adverse events reported
in the paper
Levy 2005
Methods Randomised, double-blind, placebo-controlled, multicentre, parallel-group study over
12 weeks in 22 US centres. Run-in 2 weeks single-blind placebo
Participants Population: 249 children (5 to 13) years with mild to moderate persistent asthma
Baseline characteristics: mean age 9 years. FEV1 75% predicted. Concomitant inhaled
corticosteroids used by 72% of participants.
Inclusion criteria: mild to moderate persistent asthma. FEV1 % predicted at least 50%,
bronchodilator reversibility by an increase of at least 15% in FEV1 over baseline within 30
min of inhaling albuterol 180 µg via MDI, regular use of an on-demand bronchodilator
Exclusion criteria: history of respiratory tract infection, hospitalisation due to an asthma
exacerbation in themonth prior to visit 1, clinically significantmedical condition, history
of allergy to any inhaled medications, QTc interval > 0.46 seconds, or used parenteral
or oral corticosteroids in the month prior to visit 1
Interventions 1. Formoterol 10 µg BD
2. Placebo BD
Delivery was DPI
Outcomes The primary efficacy variable was the 12-hour AUC of FEV1 at 12 weeks
“One formoterol-treated patient experienced a serious adverse event (asthma exacerba-
tion), which led to hospitalisation and discontinuation from the study. The event was
not suspected as study-drug related by the investigator.”
No web report found
Notes Sponsored by Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, matched placebo
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 227/249 (91%) completed the study
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Selective reporting (reporting bias) Low risk Serious adverse events reported in the paper
Molimard 2001
Methods Randomised, outpatients, open, parallel-group study over 3months from February 1998
to March 1999 in France. Run-in 2 to 3 weeks
Participants Population: 259 adults (18+) years with moderate persistent asthma
Baseline characteristics: mean age 39 years. FEV1 73%predicted. Concomitant inhaled
corticosteroids used by 100% of participants.
Inclusion criteria: moderate persistent asthma, daily treatment with an inhaled corti-
costeroid (the same product at a stable dose for at least 1 month prior to the first visit)
and daily treatment with inhaled bronchodilators (taken regularly or on demand). FEV1
% predicted at least 60%, bronchodilator reversibility by an increase of at least 10% in
FEV1 over baseline to be documented at the first visit or 3 months prior.
Exclusion criteria: known hypersensitivity to sympathic amines or to lactose, pregnancy
or breast-feeding, women of childbearing potential who did not use a reliable contracep-
tive method, significant change in the regular asthma medication, asthma exacerbation
or respiratory tract infection in the month prior to the first visit, incapacity to use a
metered-dose inhaler correctly or to complete the patient diary
Interventions 1. Formoterol dry-powder capsule 12 µg BD
2. Salbutamol on-demand via MDI
Outcomes The primary efficacy variable was the mean change in morning predose PEF for the
entire treatment period
“No drug-related serious AE was reported”. No report in paper of mortality or all-cause
SAE, but authors have provided additional information:
“If we consider all-cause SAE, no SAE was reported in the on-demand salbutamol group
and two SAEs were reported in the formoterol group (not suspected to be drug-related)
: one case of hospitalisation due to a malignant tumour of breast and one case of
hospitalisation due to an uterine haemorrhage. No death was reported in this study.”
Notes Supported by Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Low risk Centralised phone randomisation was used
to avoid inclusion bias
Blinding (performance bias and detection
bias)
Adverse Events
High risk Open
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Incomplete outcome data (attrition bias)
Adverse Events
Low risk 229/259 (88%) completed the study
Selective reporting (reporting bias) Low risk All-cause SAE information provided by au-
thors
Noonan 2006
Methods Randomised, double-blind, double-dummy, multicentre, placebo-controlled study over
12weeks from July 2002 to January 2004 at 84US centres (respiratory or allergy speciality
clinical practice). Run-in 2 weeks
Participants Population: 596 adolescents and adults (12 to 87) years with moderate to severe persis-
tent asthma
Baseline characteristics: mean age 41 years. FEV1 67%predicted. Concomitant inhaled
corticosteroids used by 100% of participants.
Inclusion criteria: moderate to severe persistent asthma chronically treated with a
medium to high dose of ICS, FEV1 % predicted within the entrance range of 45% to
85%, bronchodilator reversibility of FEV1 of at least 12% and 0.20 L from the pre-
albuterol baseline value within 15 to 30 minutes after administration of a standard dose
of salbutamol
Exclusion criteria: requiring hospitalisation once or emergency treatment more than
once in the preceding 6 months, greater than 10-pack per year smoking history
Interventions 1. Symbicort 320 µg/9 µg BD pMDI
2. Budesonide 320 µg BD pMDI
3. Formoterol 9 µg BD DPI
4. Placebo DPI and pMDI
Only the formoterol and placebo arms are included in this review
Outcomes The co-primary efficacy variables were baseline adjusted average 12-hour FEV I and
predose FEV I.
No all-cause SAE data reported in the paper but website indicates 2 SAEs on formoterol
and none on placebo. There were no deaths
Web data found on AstraZeneca clinical trials website SD-039-0717
Notes Sponsored by AstraZeneca
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation schedule
Allocation concealment (selection bias) Low risk Identical packages shipped to centres
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Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 60% withdrawals in placebo arm and 51.
2% in formoterol arm
Selective reporting (reporting bias) Low risk Full SAE data on website
Novartis 2005
Methods This represents results from placebo-controlled trials of at least 4 weeks duration from
the Integrated Database of Novartis Clinical Trials
Participants
Interventions 1. Formoterol 24 µg bd via Aerolizer or Certihaler
2. Formoterol 12 µg bd via Aerolizer or Certihaler
3. Placebo
4. Albuterol
Outcomes Asthma-related SAE data
Notes These data have been entered as a separate subgroup and not combinedwith other studies
as 5 of the 22 studies are already included in this review, but no separate information
has yet been received in relation to the other 17 studies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No individual study data available
Allocation concealment (selection bias) Unclear risk No individual study data available
Blinding (performance bias and detection
bias)
Adverse Events
Unclear risk No individual study data available
Incomplete outcome data (attrition bias)
Adverse Events
Unclear risk No individual study data available
Selective reporting (reporting bias) Unclear risk No individual study data available
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Pleskow 2003
Methods A randomised, double-blind, double-dummy, placebo-controlled, multicentre, parallel-
group study over 12 weeks
Participants Population: 554 adults and adolescents (12 to 75) years withmild tomoderate persistent
asthma
Baseline characteristics: mean age 33 years. FEV1 66%predicted. Concomitant inhaled
corticosteroids used by 44% of participants
Inclusion criteria: mild-to-moderate asthma, inhaled B2-selective adrenoreceptor ago-
nist on a daily basis for 2 or more months, FEV1 % predicted between 40% to 80%,
bronchodilator reversibility by an increase of at least 15% in FEV1 within 30 min after
inhalation of albuterol 180 µg, chest x-ray with normal findings or findings consistent
with asthma
Exclusion criteria: pregnant women/women child-bearing potential who did not have
reliable form of contraception; significant coronary heart disease; prior MI; uncontrolled
hypertension; diabetes; convulsive disorder; intolerance of beta-agonists; URTI within
1 month of study entry; hospitalisation for acute asthma within 1 month of study entry
or during run-in; non-compliance to medical regimes; parenteral/oral steroids in month
prior to visit 1; newly instituted/modified ICS therapy (including discontinuation);
disodium cromoglycate; oral/inhaled anticholinergics; desensitisation therapy; recent use
of astemizole; use of theophylline in month prior to visit 1; use of antiarrhythmics; use
of Prozac; vaccination with live virus in month prior to visit 1; weight 35% above or
25% predicted; significant smoking history; malignancy
Interventions 1. Formoterol 12/24 µg BD
2. Albuterol 180 µg QDS
3. Placebo QDS
Formoterol delivered by Aerolizer (dry powder) and albuterol by MDI
Outcomes Primary outcome: FEV1. Safety was evaluated by adverse event reports.
13 serious adverse events are reported in the paper but not attributed to treatment groups.
2 deaths are fully described as below
No Novartis web report found for this study. FDA submission for study 041 (http:/
/www.fda.gov/cder/foi/nda/2001/20831 Foradil medr P1.pdf ). This lists all (asthma-
related in brackets) SAE as: 1 (1) on formoterol 12 µg, 7 (5) on formoterol 24 µg, 2 (0)
on albuterol and 3 (2) on placebo
FDA documents also show 1 death from asthma with formoterol 24 µg and 1 death
from pancreatitis with albuterol (which are included in the above SAE totals)
Notes Sponsored by Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Unclear risk No information available
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Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, double-dummy
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 484/554 (87%) completed the study
Selective reporting (reporting bias) Low risk Full SAE data from FDA submission
SD-037-0344
Methods Randomised, double-blind, double-dummy, parallel-group, placebo-controlled, multi-
centre, 12-week study with a 2-week run-in period. This study was performed in 48
centres across 7 countries (Argentina, Brazil, Greece, Mexico, Philippines, Poland, South
Africa)
Participants Population: 639 adolescents and adults (12 to 80) years with asthma
Baseline characteristics: mean age 35 years. FEV1 not reported. Concomitant inhaled
corticosteroids used by 100% of participants.
Inclusion criteria: treated with 200 to 1000 µg/day of inhaled steroids for the previous
3 months and on a stable dose for 30 days prior to the start of the run-in period. For
inclusion to the treatment period, total asthma symptom score (night-time plus day-
time) of greater than 1 on at least 4 of the last 7 days of the run-in period
Interventions 1. Formoterol (HFA) 9 µg BD (pMDI)
2. Formoterol 9 µg BD (Turbuhaler)
2. Placebo BD
Outcomes Primary variable was the change from baseline (mean over last 10 days of run-in period)
to treatment (mean for the 12-week treatment period) in morning PEF before inhalation
of study treatment
“One subject, a 66-year-old male, died during this study, after 55 days of treatment with
formoterol HFA pMDI 9 mg; the investigator considered that there was no relationship
between study medication and death. Six subjects experienced a serious adverse event
(SAE) during treatment.”
No paper publication. “The HFA product will not be available on the market.”
Notes Sponsored by AstraZeneca
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
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SD-037-0344 (Continued)
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, double-dummy
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 630/639 (97%) completed the study
Selective reporting (reporting bias) Low risk Full SAE data reported
Steffensen 1995
Methods A randomised, double-blind, double-dummy, placebo-controlled, multicentre, parallel-
group study over 12 weeks at 20 centres in Scandinavia. Run-in 2 weeks
Participants Population: 304 adolescents and adults (18 to 79) years with clinically stable asthma
Baseline characteristics: mean age 48 years. Concomitant inhaled corticosteroids used
by 87% of participants. FEV1 66% predicted.
Inclusion criteria: clinically stable and use of inhaled, short-acting B2-agonist at least
1 month before the start of the trial, clinical history of reversible obstructive airway
disease, FEV1 % predicted at least 40%, bronchodilator reversibility of 15% in FEV1
over baseline 15 to 30 min after inhalation of salbutamol 400 µg
Exclusion criteria: unstable asthma, altered dose medication
Interventions 1. Formoterol 12 µg BD
2. Salbutamol 400 µg QDS
3. Placebo QDS
Delivery was dry powder device
Outcomes FEV1, FVC, PEF, rescue use, asthma symptom score. Adverse events, including asthma
exacerbations, efficacy rating
Notes Funding from Ciba Geigy (later Novartis)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, double-dummy, matching
devices
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 260/304 (85%) completed the study
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Steffensen 1995 (Continued)
Selective reporting (reporting bias) Low risk All-cause SAE described in paper by treat-
ment group
van der Molen 1997
Methods Randomised, double-blind, multicentre, placebo-controlled, parallel-group study over
24 weeks in 16 centres in Canada and The Netherlands. Patients were recruited from
10 outpatient hospital clinics in Canada and 5 out-patient clinics and 1 co-ordinating
centre for 44 Dutch general practitioners in The Netherlands. Run-in 4 weeks
Participants Population: 239 adults with mild to moderate asthma
Baseline characteristics: mean age 43 years. FEV1 67%predicted. Concomitant inhaled
corticosteroids used by 100% of participants.
Inclusion criteria: mild to moderate asthma, regular use of any dose of inhaled corti-
costeroids, at least 5 inhalations of a short acting B2-agonist per week before the entry
visit, bronchodilator reversibility by an increase of at least 15% in FEV1 over baseline
after 2 inhalations of 250 µg terbutaline or the equivalent dose of salbutamol
Exclusion criteria: oral corticosteroids at any time in the last month, smoking history of
greater than 20 pack-years, FEV1 less than 40% predicted, or an exacerbation of asthma
symptoms during the previous month
Interventions 1. Formoterol 24 µg BD
2. Placebo BD
Delivery was DPI
Outcomes The primary variable in the study was the total daily score of asthma symptoms. No
reporting in the paper of serious adverse events
No website found. Manufacturers asked for all-cause serious adverse event data. These
data gave no indication of any deaths. 4 patients with SAE on formoterol and 5 on
placebo. 1 and 3 had asthma-related SAE
Notes Supported by Astra Draco SD-037-3008
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Low risk Blocks of 4 to 1 of the 2 treatment groups
of equal size
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind
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van der Molen 1997 (Continued)
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 208/239 (87%) completed the study
Selective reporting (reporting bias) Low risk SAE data provided by sponsors
van Schayck 2002
Methods Randomised study over 12 weeks at a lung function laboratory in The Netherlands.
Run-in 8 weeks
Participants Population: 162 adolescents and adults (16 to 60) years
Baseline characteristics: mean age 35 years, FEV1 86%predicted. Concomitant inhaled
corticosteroids used by 95% of participants
Inclusion criteria: history of bronchial symptoms or a clinical diagnosis of asthma, FEV1
%predicted at least 50%, and either PC20 on histamine < 8 mg/mL
−1 or bronchodilator
reversibility by an increase of at least 15% in FEV1 over baseline after inhalation of 800
µg salbutamol
Exclusion criteria: not reported
At the start of the 8-week washout period, patients to cease all their pulmonary medi-
cation (inhaled corticosteroids, cromoglycates, bronchodilators) and to use only rescue
medication on demand
Interventions 1. Salbutamol 100 µg BD
2. Formoterol 12 µg BD
3. Placebo
Delivery was MDI
Outcomes The effects of bronchodilator use on the perception of airway obstruction
There is no indication that data on adverse events were collected. Author has confirmed
that no serious adverse events were reported in this study
Notes No support declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
Adverse Events
High risk Open?
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 128/162 (79%) completed the study
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van Schayck 2002 (Continued)
Selective reporting (reporting bias) Low risk No information on SAEs in paper but data
provided by author
Von Berg 2003
Methods A randomised, double-blind, placebo-controlled study over 12 weeks at 32 centres in 5
countries in Europe. Run-in 2 weeks
Participants Population: 248 children (6 to 17) years with mild to moderate asthma
Baseline characteristics: mean age 11 years. FEV1 81%predicted. Concomitant inhaled
corticosteroids used by 82% of participants.
Inclusion criteria: 6 to 17 years, diagnosis of asthma, ATS guidelines, at least 6 months
previously, FEV1 % predicted at least 40%, receiving anti-inflammatory agents (ICS,
OCS, nedocromil, cromones) at stable dose for 30 days, able to use Turbuhaler, and peak
flow meter, bronchodilator reversibility by either an increase of at least 15% in FEV1
over baseline or an increase of at least 9% in FEV1 predicted or an increase of at least
15% am PEF 4/8 days run-in
Exclusion criteria: use of astemizole within 60 days before inclusion, regular nasal
corticosteroids or antihistamines within 30 days, immunotherapy less than 90 days,
significant seasonal asthma or allergy, significant medical condition
Interventions 1. Formoterol 9 µg BD
2. Formoterol 4.5 µg BD
3. Placebo
Delivery was Turbuhaler
Outcomes The primary efficacy variable was morning PEF, recorded in patients’ diaries
“Nine serious AEs (SAEs) were reported in eight patients in the formoterol groups (n=3
formoterol 4.5 mcg and n=5 in formoterol 9 mcg) and one SAE in the placebo group;
none of the SAEs was considered causally related to the study drug. One death was
reported in the formoterol 9 mcg group, from a subarachnoid haemorrhage, which was
judged unlikely to be due to the study drug.” Further information has been provided by
the author to clarify that 2 patients in the formoterol 9 µg arm suffered 2 serious adverse
events (asthma and haematuria in 1 patient, and abdominal pain and appendicitis in 1
patient), so 3 patients in each formoterol arm and 1 in the placebo arm had any SAE.
The author also confirmed that the participant who died was not included in the 9 SAE
events, but was one of the 8 patients who suffered a SAE
Notes No sponsorship reported in the paper but the author confirms that the study was spon-
sored by Astra
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Consecutive patient number, 1:1:1 ratio
using computer-generated schedule
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Von Berg 2003 (Continued)
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind, identical devices
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 225/248 (91%) completed the study
Selective reporting (reporting bias) Low risk SAE report in the paper
Wolfe 2006
Methods Randomised, double-blind, multicentre, placebo-controlled, parallel-group study over
16 weeks in 194 outpatient clinics in the US. Run-in 2 weeks single-blind placebo
Participants Population: 2085 adolescents and adults (12 to 82) years with stable, persistent asthma
Baseline characteristics: mean age 38 years. FEV1 69%predicted. Concomitant inhaled
corticosteroids used by 62% of participants.
Inclusion criteria: persistent asthma, use of inhaled beta-agonist for 2 months prior to
study entry, FEV1 at least 40% of predicted normal following washout from inhaled
bronchodilator treatment, FEV1 reversibility at least 12% after inhalation of up to 4
puffs of albuterol (360 µg) at screening or documented within the past year
Exclusion criteria: hospitalisation within 1 month/treatment of exacerbation of asthma
in month prior to study entry; evidence/array of other systemic diseases; pregnancy/
failure to use reliable contraception; change to ongoing medication used to treat chronic
asthma
Interventions 1. Formoterol 12 µg BID
2. Placebo
3. Formoterol 24 µg BID
4. Open-label formoterol 12 µg BID (with up to 2 uses prn per day). This arm was not
included in the review
Delivery was DPI (Aerolizer)
Outcomes Serious asthma exacerbations (life-threatening or requiring hospitalisation) were the pri-
mary end point
“There were no deaths in the study.” SAE data not reported for all causes in the paper
but available from FDA documentation
Web data available from documents on FDA website but not yet on Novartis Clinical
Trials (16 June 2008)
Notes Sponsored by Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
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Wolfe 2006 (Continued)
Random sequence generation (selection
bias)
Low risk 1:1:1 ratio using computer-generated list of
random numbers
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind
Incomplete outcome data (attrition bias)
Adverse Events
Low risk 1791/2085 (86%) completed the study
Selective reporting (reporting bias) Low risk Paper report is not transparent on serious
adverse events from any cause in each arm
of the trial, but these data are available from
FDA documentation
Zimmerman 2004
Methods Randomised, double-blind, placebo-controlled, multicentre, parallel-group study over
12 weeks at 27 centres in Canada. Run-in 2 weeks
Participants Population: 302 children (6 to 11) years with asthma not optimally treated with inhaled
corticosteroids alone
Baseline characteristics: mean age 9 years. FEV1 78% predicted. Concomitant inhaled
corticosteroids used by 100% of participants.
Inclusion criteria: aged 6 to 11 years with a clinical diagnosis of asthma according to
American Thoracic Society criteria for at least 6 months, FEV1 % predicted of 50% to
90%, bronchodilator reversibility of at least 15%, or at least 9% of predicted normal,
treatment with regular inhaled corticosteroids for at least 3 months before trial entry,
asthma symptoms sufficient to suggest that additional therapy might be needed
Exclusion criteria: known or suspected hypersensitivity to formoterol or inhaled lactose,
deteriorating asthma or a respiratory infection, clinically significant concurrent disease,
significant seasonal allergy, or if smokers, taken disallowed asthma medications before
trial entry, oral corticosteroids or antileukotrienes within 30 days, astemizole within 60
days, sodium cromoglycate or ketotifen within 7 days, salmeterol or formoterol within
72 hours, xanthines or antihistamines within 48 hours
Interventions 1. Formoterol 4.5 µg or 9 µg BD
2. Placebo BD
Delivery was DPI
Outcomes The primary efficacy variable was change from baseline in morning peak expiratory flow
(PEF)
No information in the paper on SAEs. Manufacturers asked for all-cause serious adverse
event data: no deaths were reported. Placebo - 1 patient with SAE due to asthma.
Formoterol 4.5 - 1 patient with SAE due to dog bite. Formoterol 9 - 2 patients with
SAE due to URTI and asthma
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Zimmerman 2004 (Continued)
AZ study code DC-037-0002
Notes No support declared in the paper, but data on file with AstraZeneca
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
Adverse Events
Low risk Double-blind
Incomplete outcome data (attrition bias)
Adverse Events
Unclear risk 267/302 (88%) completed the study
Selective reporting (reporting bias) Low risk SAE data provided by sponsors
AE: adverse event; ATS: American Thoracic Society; AUC: area under curve; BD: twice a day; BDP: budesonide dipropionate;
CS: corticosteroids; DPI: dry powder inhaler; ECG: electrocardiogram; FDA: Food and Drug Administration (USA); FEV1:
forced expiratory volume in one second; FVC: forced vital capacity; ICS: inhaled corticosteroids; ITT: intention-to-treat; MAOI:
monoamine oxidase inhibitors; MDI: metered-dose inhaler; MI: myocardial infarction; NSAIDs: nonsteroidal anti-inflammatory
drugs; OS: oral steroids; PEF: peak expiratory flow; pMDI: pressurised metered-dose inhaler; QDS: four times a day; RT: respiratory
tract; SABA: short-acting beta2-agonist; SAE: serious adverse event; URTI: upper respiratory tract infection
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adler 2006 2-week study
Akpinarli 1999 6-week treatment periods
Ankerst 2003 Short-term high-dose tolerance study
Arvidsson 1989 2-week study
Aziz 1998 Volunteers (not asthmatics)
Bauer 1995 Single dose
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(Continued)
Behling 1999 3-week study
Boner 1994 Single dose
Bousquet 2005 Single dose
Bousquet 2005a Single dose
Brambilla 2003 4-week study
Bronsky 2002 Single dose
Bronsky 2004 Single dose
Brusasco 2002 Single dose
Burgess 1998 Single dose
Cazzola 2002 Single dose
Ceylan 2004 Formoterol versus montelukast
Chetta 1993 Single dose
Cheung 2006 3-week study
Chuchalin 2002 Formoterol randomised with budesonide
Chuchalin 2005 1-week study
Chuchalin 2005a Formoterol randomised with budesonide
Chung 1995 Cross-over design
Dahl 2004 Device comparison
Daugbjerg 1996 Single dose
Dey 2005 Cross-over design
Dietrich 2006 Device comparison
Dubakiene 2006 Device comparison
Dusser 2005 HFA versus DPI delivery comparison
Ericsson 2006 Randomised with budesonide
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(Continued)
Eryonucu 2005 Single dose
Ferrari 2000 Single dose
Fitoussi 2002 3-day study
Gessner 2003 8-week study
Graff-Lonnevig 1990 Cross-over design
Green 2006 Cross-over design
Happonen 2009 Cross-over study comparing formoterol Easyhaler with Foradil Aerolizer
Hedenstrom 1992 Cross-over design
Hermansen 2006 EIB single doses
Houghton 2004 Single dose
Ind 2002 Formoterol used as reliever
Jain 2004 Formoterol used as reliever
Jenkins 2005 6-week treatment periods
Kamenov 2007 Formoterol - HFA metered-dose inhaler compared to formoterol dry powder inhaler
Kesten 1992 Not RCT
Kohler 2003 Acute asthma
Kruse 2005 Cross-over design
Lebecque 1994 Single dose
Lebecque 1994a Single dose
Lee-Wong 2008 Acute asthma
Lemaigre 2006 Single dose
Lotvall 1997 Single dose
Lotvall 2005 Formoterol as reliever
Lotvall 2008 Single dose
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(Continued)
Lyseng-Williamson 2003 Not RCT
Maesen 1992 Short-term study over 3 days
Maesen 1992a Delivery device and dose
Malo 1990 Single dose
Malolepszy 2001 Formoterol versus theophylline
Malolepszy 2002 Acute asthma
Mann 2003 Overview of 3 included studies: Bensch 2001; Bensch 2002; Pleskow 2003
Marzo 2000 Healthy volunteers
Matthys 2004 3-week study
Midgren 1992 4-week study
Molimard 2005 Cumulative dose study
Najafizadeh 2007 Acute asthma
Nandeuil 2006 8-day study
Newnham 1994 4-week study
Newnham 1995 4-week study
Novartis 2005b Both arms received formoterol maintenance
Otto-Knapp 2008 4-week study
Patessio 1991 EIB
Pauwels 2003 Formoterol as reliever
Pearlman 2002 Overview of other studies
Pohunek 2004 Single dose
Price 2002 Randomised together with budesonide
Price 2008 Overview of safety data from AstraZeneca-sponsored trials of duration of at least 4 weeks
Randell 2005 Device comparison
63Regular treatment with formoterol for chronic asthma: serious adverse events (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Richter 2007 Dosage comparison
Rico-Mendez 1999 Study included patients with chronic bronchitis
Ringdal 1998 Single dose
Rosenborg 2000 Single dose
Rosenborg 2002 Short-term dose-response study
Rosenborg 2002a Short-term dose-response study
Rubinfeld 2006 Acute asthma
Schlimmer 2002 Acute asthma
Sprogoe 1992 6-week study
Stahl 2003 Formoterol as reliever
Stelmach 2008 Study on exercise-induced bronchospasm
Tattersfield 1999 Description of exacerbations in FACET study
Tattersfield 2001 As-needed formoterol
Totterman 1998 3-day study
van den Berg 1995 8-day study
van der Woude 2004 Single dose
van Veen 2003 2-week cross-over
Verini 1998 5-day study
Villa 2002 As-needed formoterol
Villa 2002a As-needed formoterol
Vilsvik 2001 EIB
Wallin 1999 8-week study
Wegener 1992 Single dose
Wong 1992 Single dose
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(Continued)
Yasuo 1984 4-week study
Yasuo 1984a Single dose
Yasuo 1984b Single dose
Yates 1995 2-week cross-over
Yurdakul 2002 No placebo or SABA control
DPI: dry powder inhaler; EIB: exercise induced bronchoconstriction; HFA: hydrofluoroalkane; RCT: randomised controlled trial;
SABA: short-acting beta2-agonist
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D A T A A N D A N A L Y S E S
Comparison 1. All-cause mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall results 14 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 14 5463 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.50 [0.41, 49.49]
1.2 Formoterol versus
salbutamol
6 1418 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.47 [0.02, 8.98]
Comparison 2. Adults and children non-fatal serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
19 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 19 6646 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.57 [1.06, 2.31]
1.2 Formoterol versus
salbutamol
9 2119 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.73 [0.37, 1.43]
Comparison 3. Adults and children non-fatal serious adverse events (without formoterol 24 µg arms)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
18 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 18 5438 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.55 [0.97, 2.48]
1.2 Formoterol versus
salbutamol
9 1848 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.41 [0.19, 0.90]
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Comparison 4. Adults with non-fatal serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
15 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 15 5311 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.23 [0.76, 1.99]
1.2 Formoterol versus
salbutamol
9 2119 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.73 [0.37, 1.43]
Comparison 5. Children with non-fatal serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
5 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 5 1335 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.48 [1.27, 4.83]
1.2 Formoterol versus
salbutamol
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Children with non-fatal serious adverse events (without formoterol 24 µg arms)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
5 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 5 1164 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.52 [1.15, 5.51]
1.2 Formoterol versus
salbutamol
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Dose comparison: formoterol 24 µg versus 12 µg twice daily
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events 5 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Adults (all-cause) 3 1598 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.35 [0.64, 2.85]
1.2 Children (all-cause) 1 342 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.20 [0.52, 2.74]
1.3 Asthma SAE 1 3104 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.16 [1.13, 4.11]
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Comparison 8. Adults and children fatal and non-fatal serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
19 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 19 6646 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.61 [1.09, 2.37]
1.2 Formoterol versus
salbutamol
9 2119 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.37, 1.38]
Comparison 9. Asthma mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
12 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 12 4522 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.54 [0.07, 285.25]
1.2 Formoterol versus
salbutamol
6 1418 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.49 [0.07, 286.29]
Comparison 10. Cardiovascular mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
12 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 12 4522 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.54 [0.07, 285.29]
1.2 Formoterol versus
salbutamol
6 1418 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 11. Adults and children non-fatal asthma-related serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
17 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 17 5759 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.99 [1.12, 3.53]
1.2 Formoterol versus
salbutamol
9 2119 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.74 [0.29, 1.88]
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Comparison 12. Adults and children non-fatal asthma-related serious adverse events (Novartis data)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
11 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo
(Novartis published data)
10 4138 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.06 [1.57, 5.96]
1.2 Formoterol versus placebo
(Novartis integrated database)
1 5631 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.81 [1.54, 5.14]
Comparison 13. Hospitalisations for asthma
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
7 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 7 3433 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.28 [1.65, 6.52]
1.2 Formoterol versus
salbutamol
2 593 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.75 [0.41, 7.49]
Comparison 14. Adults and children non-fatal cardiovascular serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
8 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 8 3049 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.09, 5.21]
1.2 Formoterol versus
salbutamol
5 803 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.14 [0.01, 1.33]
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Comparison 15. Impact of inhaled corticosteroids on asthma-related SAEs
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patients with at least one
asthma-related SAE
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Patients taking inhaled
corticosteroids (all doses of
formoterol))
1 3807 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.58 [1.21, 5.49]
1.2 Patients not taking inhaled
corticosteroids (all doses of
formoterol)
1 1824 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.22 [1.17, 8.89]
1.3 Patients taking inhaled
corticosteroids (formoterol 12
mcg twice daily)
1 2708 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.76 [1.06, 7.15]
1.4 Patients not taking inhaled
corticosteroids (formoterol 12
mcg twice daily)
1 1103 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.71 [0.75, 18.48]
Comparison 16. Adults and children published non-fatal serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
7 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 7 1792 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.31 [1.17, 4.53]
1.2 Formoterol versus
salbutamol
3 536 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.60 [0.15, 2.44]
Comparison 17. Adults and children all adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
11 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 11 4884 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.11 [0.98, 1.25]
1.2 Formoterol versus
salbutamol
4 1151 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.98 [0.76, 1.26]
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Comparison 18. Adults and children published adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 8 3743 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.94, 1.26]
1.2 Formoterol versus
salbutamol
4 1151 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.76, 1.26]
Comparison 19. Adults and children all published drug-related adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
4 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 4 2112 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.42 [1.07, 1.88]
1.2 Formoterol versus
salbutamol
3 542 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.75 [0.48, 1.18]
Comparison 20. Adults and children serious drug-related adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Formoterol versus placebo or
salbutamol
9 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol versus placebo 9 3618 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.45 [0.18, 11.61]
1.2 Formoterol versus
salbutamol
3 746 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.04, 12.34]
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Analysis 1.1. Comparison 1 All-cause mortality, Outcome 1 Overall results.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 1 All-cause mortality
Outcome: 1 Overall results
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2001 0/271 0/136 0.0 [ 0.0, 0.0 ]
Bensch 2002 0/342 0/176 0.0 [ 0.0, 0.0 ]
Busse 2004 0/80 0/80 0.0 [ 0.0, 0.0 ]
Corren 2007 0/123 0/131 0.0 [ 0.0, 0.0 ]
FitzGerald 1999 0/89 0/91 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 0/91 0.0 [ 0.0, 0.0 ]
Molimard 2001 0/130 0/129 0.0 [ 0.0, 0.0 ]
Noonan 2006 0/123 0/125 0.0 [ 0.0, 0.0 ]
Pleskow 2003 1/275 0/141 4.54 [ 0.07, 285.25 ]
SD-037-0344 1/429 0/210 4.43 [ 0.07, 287.77 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Von Berg 2003 1/164 0/84 4.54 [ 0.07, 285.29 ]
Wolfe 2006 0/1054 0/514 0.0 [ 0.0, 0.0 ]
Zimmerman 2004 0/201 0/101 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 3413 2050 4.50 [ 0.41, 49.49 ]
Total events: 3 (Formoterol), 0 (Control)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
2 Formoterol versus salbutamol
Bensch 2001 0/271 0/134 0.0 [ 0.0, 0.0 ]
Busse 2004 0/80 0/79 0.0 [ 0.0, 0.0 ]
FitzGerald 1999 0/89 0/91 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 0/88 0.0 [ 0.0, 0.0 ]
Pleskow 2003 1/275 1/138 0.47 [ 0.02, 8.98 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 847 571 0.47 [ 0.02, 8.98 ]
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Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 1 (Formoterol), 1 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
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Analysis 2.1. Comparison 2 Adults and children non-fatal serious adverse events, Outcome 1 Formoterol
versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 2 Adults and children non-fatal serious adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2001 6/271 1/136 2.39 [ 0.49, 11.65 ]
Bensch 2002 24/342 3/176 2.92 [ 1.29, 6.62 ]
Busse 2004 2/80 0/80 7.48 [ 0.46, 120.69 ]
Corren 2007 0/123 2/131 0.14 [ 0.01, 2.30 ]
Ekstrom 1998 1/135 2/129 0.49 [ 0.05, 4.73 ]
Ekstrom 1998a 0/114 2/113 0.13 [ 0.01, 2.14 ]
FitzGerald 1999 1/89 3/91 0.37 [ 0.05, 2.67 ]
LaForce 2005 1/86 0/91 7.83 [ 0.16, 395.30 ]
Levy 2005 1/127 0/122 7.10 [ 0.14, 358.29 ]
Molimard 2001 2/130 0/129 7.39 [ 0.46, 118.78 ]
Noonan 2006 2/123 0/125 7.57 [ 0.47, 121.75 ]
Pleskow 2003 7/275 3/141 1.19 [ 0.32, 4.49 ]
SD-037-0344 5/429 1/210 2.10 [ 0.38, 11.59 ]
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Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Steffensen 1995 0/103 2/101 0.13 [ 0.01, 2.11 ]
van der Molen 1997 4/125 5/114 0.72 [ 0.19, 2.73 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Von Berg 2003 6/164 1/84 2.45 [ 0.50, 11.95 ]
Wolfe 2006 16/1054 5/514 1.51 [ 0.60, 3.78 ]
Zimmerman 2004 3/201 1/101 1.47 [ 0.18, 11.83 ]
Subtotal (95% CI) 4017 2629 1.57 [ 1.06, 2.31 ]
Total events: 81 (Formoterol), 31 (Control)
Heterogeneity: Chi2 = 21.28, df = 17 (P = 0.21); I2 =20%
Test for overall effect: Z = 2.25 (P = 0.025)
2 Formoterol versus salbutamol
Bensch 2001 6/271 2/134 1.45 [ 0.33, 6.41 ]
Busse 2004 2/80 3/79 0.65 [ 0.11, 3.87 ]
Ekstrom 1998 1/135 3/133 0.36 [ 0.05, 2.57 ]
Ekstrom 1998a 0/114 4/116 0.13 [ 0.02, 0.96 ]
FitzGerald 1999 1/89 3/91 0.37 [ 0.05, 2.67 ]
LaForce 2005 1/86 2/88 0.52 [ 0.05, 5.08 ]
Pleskow 2003 7/275 1/138 2.60 [ 0.59, 11.45 ]
Steffensen 1995 0/103 0/100 0.0 [ 0.0, 0.0 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1199 920 0.73 [ 0.37, 1.43 ]
Total events: 18 (Formoterol), 18 (Control)
Heterogeneity: Chi2 = 7.53, df = 6 (P = 0.27); I2 =20%
Test for overall effect: Z = 0.92 (P = 0.36)
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Analysis 3.1. Comparison 3 Adults and children non-fatal serious adverse events (without formoterol 24 µg
arms), Outcome 1 Formoterol versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 3 Adults and children non-fatal serious adverse events (without formoterol 24 g arms)
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2001 1/136 1/136 1.00 [ 0.06, 16.07 ]
Bensch 2002 11/171 3/176 3.38 [ 1.16, 9.83 ]
Busse 2004 2/80 0/80 7.48 [ 0.46, 120.69 ]
Corren 2007 0/123 2/131 0.14 [ 0.01, 2.30 ]
Ekstrom 1998 1/135 2/129 0.49 [ 0.05, 4.73 ]
Ekstrom 1998a 0/114 2/113 0.13 [ 0.01, 2.14 ]
FitzGerald 1999 1/89 3/91 0.37 [ 0.05, 2.67 ]
LaForce 2005 1/86 0/91 7.83 [ 0.16, 395.30 ]
Levy 2005 1/127 0/122 7.10 [ 0.14, 358.29 ]
Molimard 2001 2/130 0/129 7.39 [ 0.46, 118.78 ]
Noonan 2006 2/123 0/125 7.57 [ 0.47, 121.75 ]
Pleskow 2003 1/139 3/141 0.37 [ 0.05, 2.65 ]
SD-037-0344 5/429 1/210 2.10 [ 0.38, 11.59 ]
Steffensen 1995 0/103 2/101 0.13 [ 0.01, 2.11 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Von Berg 2003 6/164 1/84 2.45 [ 0.50, 11.95 ]
Wolfe 2006 10/527 5/514 1.92 [ 0.69, 5.31 ]
Zimmerman 2004 3/201 1/101 1.47 [ 0.18, 11.83 ]
Subtotal (95% CI) 2923 2515 1.55 [ 0.97, 2.48 ]
Total events: 47 (Formoterol), 26 (Control)
Heterogeneity: Chi2 = 21.60, df = 16 (P = 0.16); I2 =26%
Test for overall effect: Z = 1.84 (P = 0.065)
2 Formoterol versus salbutamol
Bensch 2001 1/136 2/134 0.50 [ 0.05, 4.88 ]
Busse 2004 2/80 3/79 0.65 [ 0.11, 3.87 ]
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Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Ekstrom 1998 1/135 3/133 0.36 [ 0.05, 2.57 ]
Ekstrom 1998a 0/114 4/116 0.13 [ 0.02, 0.96 ]
FitzGerald 1999 1/89 3/91 0.37 [ 0.05, 2.67 ]
LaForce 2005 1/86 2/88 0.52 [ 0.05, 5.08 ]
Pleskow 2003 1/139 1/138 0.99 [ 0.06, 15.95 ]
Steffensen 1995 0/103 0/100 0.0 [ 0.0, 0.0 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 928 920 0.41 [ 0.19, 0.90 ]
Total events: 7 (Formoterol), 18 (Control)
Heterogeneity: Chi2 = 1.99, df = 6 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
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Analysis 4.1. Comparison 4 Adults with non-fatal serious adverse events, Outcome 1 Formoterol versus
placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 4 Adults with non-fatal serious adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2001 6/271 1/136 2.39 [ 0.49, 11.65 ]
Busse 2004 2/80 0/80 7.48 [ 0.46, 120.69 ]
Corren 2007 0/114 1/122 0.14 [ 0.00, 7.30 ]
Ekstrom 1998 1/135 2/129 0.49 [ 0.05, 4.73 ]
Ekstrom 1998a 0/114 2/113 0.13 [ 0.01, 2.14 ]
FitzGerald 1999 1/89 3/91 0.37 [ 0.05, 2.67 ]
LaForce 2005 1/86 0/91 7.83 [ 0.16, 395.30 ]
Molimard 2001 2/130 0/129 7.39 [ 0.46, 118.78 ]
Noonan 2006 2/123 0/125 7.57 [ 0.47, 121.75 ]
Pleskow 2003 7/275 3/141 1.19 [ 0.32, 4.49 ]
SD-037-0344 5/429 1/210 2.10 [ 0.38, 11.59 ]
Steffensen 1995 0/103 2/101 0.13 [ 0.01, 2.11 ]
van der Molen 1997 4/125 5/114 0.72 [ 0.19, 2.73 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Wolfe 2006 16/1054 5/514 1.51 [ 0.60, 3.78 ]
Subtotal (95% CI) 3174 2137 1.23 [ 0.76, 1.99 ]
Total events: 47 (Formoterol), 25 (Control)
Heterogeneity: Chi2 = 15.74, df = 13 (P = 0.26); I2 =17%
Test for overall effect: Z = 0.83 (P = 0.40)
2 Formoterol versus salbutamol
Bensch 2001 6/271 2/134 1.45 [ 0.33, 6.41 ]
Busse 2004 2/80 3/79 0.65 [ 0.11, 3.87 ]
Ekstrom 1998 1/135 3/133 0.36 [ 0.05, 2.57 ]
Ekstrom 1998a 0/114 4/116 0.13 [ 0.02, 0.96 ]
FitzGerald 1999 1/89 3/91 0.37 [ 0.05, 2.67 ]
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Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
LaForce 2005 1/86 2/88 0.52 [ 0.05, 5.08 ]
Pleskow 2003 7/275 1/138 2.60 [ 0.59, 11.45 ]
Steffensen 1995 0/103 0/100 0.0 [ 0.0, 0.0 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1199 920 0.73 [ 0.37, 1.43 ]
Total events: 18 (Formoterol), 18 (Control)
Heterogeneity: Chi2 = 7.53, df = 6 (P = 0.27); I2 =20%
Test for overall effect: Z = 0.92 (P = 0.36)
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Analysis 5.1. Comparison 5 Children with non-fatal serious adverse events, Outcome 1 Formoterol versus
placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 5 Children with non-fatal serious adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2002 24/342 3/176 66.4 % 2.92 [ 1.29, 6.62 ]
Corren 2007 0/9 1/9 2.9 % 0.14 [ 0.00, 6.82 ]
Levy 2005 1/127 0/122 2.9 % 7.10 [ 0.14, 358.29 ]
Von Berg 2003 6/164 1/84 17.7 % 2.45 [ 0.50, 11.95 ]
Zimmerman 2004 3/201 1/101 10.2 % 1.47 [ 0.18, 11.83 ]
Subtotal (95% CI) 843 492 100.0 % 2.48 [ 1.27, 4.83 ]
Total events: 34 (Formoterol), 6 (Control)
Heterogeneity: Chi2 = 2.79, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.67 (P = 0.0075)
2 Formoterol versus salbutamol
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Study or subgroup Formoterol Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 6.1. Comparison 6 Children with non-fatal serious adverse events (without formoterol 24 µg
arms), Outcome 1 Formoterol versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 6 Children with non-fatal serious adverse events (without formoterol 24 g arms)
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2002 11/171 3/176 53.6 % 3.38 [ 1.16, 9.83 ]
Corren 2007 0/9 1/9 4.0 % 0.14 [ 0.00, 6.82 ]
Levy 2005 1/127 0/122 4.0 % 7.10 [ 0.14, 358.29 ]
Von Berg 2003 6/164 1/84 24.4 % 2.45 [ 0.50, 11.95 ]
Zimmerman 2004 3/201 1/101 14.0 % 1.47 [ 0.18, 11.83 ]
Subtotal (95% CI) 672 492 100.0 % 2.52 [ 1.15, 5.51 ]
Total events: 21 (Formoterol), 6 (Control)
Heterogeneity: Chi2 = 2.96, df = 4 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
2 Formoterol versus salbutamol
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.1. Comparison 7 Dose comparison: formoterol 24 µg versus 12 µg twice daily, Outcome 1
Serious adverse events.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 7 Dose comparison: formoterol 24 g versus 12 g twice daily
Outcome: 1 Serious adverse events
Study or subgroup Formoterol 24 mcg Formoterol 12 mcg
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults (all-cause)
Bensch 2001 5/135 1/136 21.4 % 3.92 [ 0.78, 19.71 ]
Pleskow 2003 6/136 1/139 24.9 % 4.41 [ 0.98, 19.71 ]
Wolfe 2006 5/525 10/527 53.8 % 0.51 [ 0.18, 1.41 ]
Subtotal (95% CI) 796 802 100.0 % 1.35 [ 0.64, 2.85 ]
Total events: 16 (Formoterol 24 mcg), 12 (Formoterol 12 mcg)
Heterogeneity: Chi2 = 7.56, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Children (all-cause)
Bensch 2002 13/171 11/171 100.0 % 1.20 [ 0.52, 2.74 ]
Subtotal (95% CI) 171 171 100.0 % 1.20 [ 0.52, 2.74 ]
Total events: 13 (Formoterol 24 mcg), 11 (Formoterol 12 mcg)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
3 Asthma SAE
Novartis 2005 22/1156 18/1948 100.0 % 2.16 [ 1.13, 4.11 ]
Subtotal (95% CI) 1156 1948 100.0 % 2.16 [ 1.13, 4.11 ]
Total events: 22 (Formoterol 24 mcg), 18 (Formoterol 12 mcg)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
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Analysis 8.1. Comparison 8 Adults and children fatal and non-fatal serious adverse events, Outcome 1
Formoterol versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 8 Adults and children fatal and non-fatal serious adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2001 6/271 1/136 2.39 [ 0.49, 11.65 ]
Bensch 2002 24/342 3/176 2.92 [ 1.29, 6.62 ]
Busse 2004 2/80 0/80 7.48 [ 0.46, 120.69 ]
Corren 2007 0/123 2/131 0.14 [ 0.01, 2.30 ]
Ekstrom 1998 1/135 2/129 0.49 [ 0.05, 4.73 ]
Ekstrom 1998a 0/114 2/113 0.13 [ 0.01, 2.14 ]
FitzGerald 1999 1/89 3/91 0.37 [ 0.05, 2.67 ]
LaForce 2005 1/86 0/91 7.83 [ 0.16, 395.30 ]
Levy 2005 1/127 0/122 7.10 [ 0.14, 358.29 ]
Molimard 2001 2/130 0/129 7.39 [ 0.46, 118.78 ]
Noonan 2006 2/123 0/125 7.57 [ 0.47, 121.75 ]
Pleskow 2003 8/275 3/141 1.35 [ 0.38, 4.79 ]
SD-037-0344 6/429 1/210 2.34 [ 0.48, 11.41 ]
Steffensen 1995 0/103 2/101 0.13 [ 0.01, 2.11 ]
van der Molen 1997 4/125 5/114 0.72 [ 0.19, 2.73 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Von Berg 2003 7/164 1/84 2.67 [ 0.60, 11.79 ]
Wolfe 2006 16/1054 5/514 1.51 [ 0.60, 3.78 ]
Zimmerman 2004 3/201 1/101 1.47 [ 0.18, 11.83 ]
Subtotal (95% CI) 4017 2629 1.61 [ 1.09, 2.37 ]
Total events: 84 (Formoterol), 31 (Control)
Heterogeneity: Chi2 = 21.47, df = 17 (P = 0.21); I2 =21%
Test for overall effect: Z = 2.42 (P = 0.016)
2 Formoterol versus salbutamol
Bensch 2001 6/271 2/134 1.45 [ 0.33, 6.41 ]
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Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Busse 2004 2/80 3/79 0.65 [ 0.11, 3.87 ]
Ekstrom 1998 1/135 3/133 0.36 [ 0.05, 2.57 ]
Ekstrom 1998a 0/114 4/116 0.13 [ 0.02, 0.96 ]
FitzGerald 1999 1/89 3/91 0.37 [ 0.05, 2.67 ]
LaForce 2005 1/86 2/88 0.52 [ 0.05, 5.08 ]
Pleskow 2003 8/275 2/138 1.85 [ 0.49, 6.99 ]
Steffensen 1995 0/103 0/100 0.0 [ 0.0, 0.0 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1199 920 0.71 [ 0.37, 1.38 ]
Total events: 19 (Formoterol), 19 (Control)
Heterogeneity: Chi2 = 6.59, df = 6 (P = 0.36); I2 =9%
Test for overall effect: Z = 1.00 (P = 0.32)
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Analysis 9.1. Comparison 9 Asthma mortality, Outcome 1 Formoterol versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 9 Asthma mortality
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2001 0/271 0/136 0.0 [ 0.0, 0.0 ]
Bensch 2002 0/342 0/176 0.0 [ 0.0, 0.0 ]
Busse 2004 0/80 0/80 0.0 [ 0.0, 0.0 ]
Corren 2007 0/123 0/131 0.0 [ 0.0, 0.0 ]
FitzGerald 1999 0/89 0/91 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 0/91 0.0 [ 0.0, 0.0 ]
Molimard 2001 0/130 0/129 0.0 [ 0.0, 0.0 ]
Noonan 2006 0/123 0/125 0.0 [ 0.0, 0.0 ]
Pleskow 2003 1/275 0/141 4.54 [ 0.07, 285.25 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Von Berg 2003 0/164 0/84 0.0 [ 0.0, 0.0 ]
Wolfe 2006 0/1054 0/514 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 2783 1739 4.54 [ 0.07, 285.25 ]
Total events: 1 (Formoterol), 0 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Formoterol versus salbutamol
Bensch 2001 0/271 0/134 0.0 [ 0.0, 0.0 ]
Busse 2004 0/80 0/79 0.0 [ 0.0, 0.0 ]
FitzGerald 1999 0/89 0/91 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 0/88 0.0 [ 0.0, 0.0 ]
Pleskow 2003 1/275 0/138 4.49 [ 0.07, 286.29 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 847 571 4.49 [ 0.07, 286.29 ]
Total events: 1 (Formoterol), 0 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
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Analysis 10.1. Comparison 10 Cardiovascular mortality, Outcome 1 Formoterol versus placebo or
salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 10 Cardiovascular mortality
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2001 0/271 0/136 0.0 [ 0.0, 0.0 ]
Bensch 2002 0/342 0/176 0.0 [ 0.0, 0.0 ]
Busse 2004 0/80 0/80 0.0 [ 0.0, 0.0 ]
Corren 2007 0/123 0/131 0.0 [ 0.0, 0.0 ]
FitzGerald 1999 0/89 0/91 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 0/91 0.0 [ 0.0, 0.0 ]
Molimard 2001 0/130 0/129 0.0 [ 0.0, 0.0 ]
Noonan 2006 0/123 0/125 0.0 [ 0.0, 0.0 ]
Pleskow 2003 0/275 0/141 0.0 [ 0.0, 0.0 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Von Berg 2003 1/164 0/84 4.54 [ 0.07, 285.29 ]
Wolfe 2006 0/1054 0/514 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 2783 1739 4.54 [ 0.07, 285.29 ]
Total events: 1 (Formoterol), 0 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Formoterol versus salbutamol
Bensch 2001 0/271 0/134 0.0 [ 0.0, 0.0 ]
Busse 2004 0/80 0/79 0.0 [ 0.0, 0.0 ]
FitzGerald 1999 0/89 0/91 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 0/88 0.0 [ 0.0, 0.0 ]
Pleskow 2003 0/275 0/138 0.0 [ 0.0, 0.0 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 847 571 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol), 0 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 11.1. Comparison 11 Adults and children non-fatal asthma-related serious adverse events,
Outcome 1 Formoterol versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 11 Adults and children non-fatal asthma-related serious adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2001 4/271 0/136 4.54 [ 0.56, 36.54 ]
Bensch 2002 19/342 0/176 4.80 [ 1.83, 12.62 ]
Busse 2004 1/80 0/80 7.39 [ 0.15, 372.38 ]
Corren 2007 0/123 0/131 0.0 [ 0.0, 0.0 ]
Ekstrom 1998 0/135 1/129 0.13 [ 0.00, 6.52 ]
Ekstrom 1998a 0/114 2/113 0.13 [ 0.01, 2.14 ]
FitzGerald 1999 0/89 0/91 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 0/91 0.0 [ 0.0, 0.0 ]
Levy 2005 1/127 0/122 7.10 [ 0.14, 358.29 ]
Molimard 2001 0/130 0/129 0.0 [ 0.0, 0.0 ]
Pleskow 2003 5/275 2/141 1.27 [ 0.26, 6.16 ]
Steffensen 1995 0/103 1/101 0.13 [ 0.00, 6.69 ]
van der Molen 1997 1/125 3/114 0.33 [ 0.05, 2.38 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Von Berg 2003 4/164 0/84 4.62 [ 0.58, 37.12 ]
Wolfe 2006 5/1054 1/514 2.08 [ 0.38, 11.48 ]
Zimmerman 2004 1/201 1/101 0.47 [ 0.03, 8.99 ]
Subtotal (95% CI) 3465 2294 1.99 [ 1.12, 3.53 ]
Total events: 41 (Formoterol), 11 (Control)
Heterogeneity: Chi2 = 17.01, df = 11 (P = 0.11); I2 =35%
Test for overall effect: Z = 2.35 (P = 0.019)
2 Formoterol versus salbutamol
Bensch 2001 4/271 2/134 0.99 [ 0.18, 5.47 ]
Busse 2004 1/80 0/79 7.30 [ 0.14, 367.79 ]
Ekstrom 1998 0/135 2/133 0.13 [ 0.01, 2.13 ]
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(. . . Continued)
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Ekstrom 1998a 0/114 3/116 0.14 [ 0.01, 1.31 ]
FitzGerald 1999 0/89 2/91 0.14 [ 0.01, 2.20 ]
LaForce 2005 0/86 0/88 0.0 [ 0.0, 0.0 ]
Pleskow 2003 5/275 0/138 4.56 [ 0.70, 29.49 ]
Steffensen 1995 0/103 0/100 0.0 [ 0.0, 0.0 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1199 920 0.74 [ 0.29, 1.88 ]
Total events: 10 (Formoterol), 9 (Control)
Heterogeneity: Chi2 = 10.10, df = 5 (P = 0.07); I2 =50%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 12.1. Comparison 12 Adults and children non-fatal asthma-related serious adverse events
(Novartis data), Outcome 1 Formoterol versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 12 Adults and children non-fatal asthma-related serious adverse events (Novartis data)
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo (Novartis published data)
Bensch 2001 4/271 0/136 4.54 [ 0.56, 36.54 ]
Bensch 2002 19/342 0/176 4.80 [ 1.83, 12.62 ]
Busse 2004 1/80 0/80 7.39 [ 0.15, 372.38 ]
FitzGerald 1999 0/89 0/91 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 0/91 0.0 [ 0.0, 0.0 ]
Levy 2005 1/127 0/122 7.10 [ 0.14, 358.29 ]
Molimard 2001 0/130 0/129 0.0 [ 0.0, 0.0 ]
Pleskow 2003 5/275 2/141 1.27 [ 0.26, 6.16 ]
Steffensen 1995 0/103 1/101 0.13 [ 0.00, 6.69 ]
Wolfe 2006 5/1054 1/514 2.08 [ 0.38, 11.48 ]
Subtotal (95% CI) 2557 1581 3.06 [ 1.57, 5.96 ]
Total events: 35 (Formoterol), 4 (Control)
Heterogeneity: Chi2 = 5.19, df = 6 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
2 Formoterol versus placebo (Novartis integrated database)
Novartis 2005 43/3768 5/1863 2.81 [ 1.54, 5.14 ]
Subtotal (95% CI) 3768 1863 2.81 [ 1.54, 5.14 ]
Total events: 43 (Formoterol), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.00080)
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Analysis 13.1. Comparison 13 Hospitalisations for asthma, Outcome 1 Formoterol versus placebo or
salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 13 Hospitalisations for asthma
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2002 18/342 0/176 4.79 [ 1.78, 12.91 ]
Corren 2007 0/123 0/131 0.0 [ 0.0, 0.0 ]
FitzGerald 1999 0/89 0/91 0.0 [ 0.0, 0.0 ]
Levy 2005 1/127 0/122 7.10 [ 0.14, 358.29 ]
Pleskow 2003 6/275 2/141 1.50 [ 0.34, 6.55 ]
Von Berg 2003 4/164 0/84 4.62 [ 0.58, 37.12 ]
Wolfe 2006 5/1054 1/514 2.08 [ 0.38, 11.48 ]
Subtotal (95% CI) 2174 1259 3.28 [ 1.65, 6.52 ]
Total events: 34 (Formoterol), 3 (Control)
Heterogeneity: Chi2 = 2.17, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00072)
2 Formoterol versus salbutamol
FitzGerald 1999 0/89 2/91 0.14 [ 0.01, 2.20 ]
Pleskow 2003 6/275 0/138 4.57 [ 0.83, 25.20 ]
Subtotal (95% CI) 364 229 1.75 [ 0.41, 7.49 ]
Total events: 6 (Formoterol), 2 (Control)
Heterogeneity: Chi2 = 4.45, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.75 (P = 0.45)
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Analysis 14.1. Comparison 14 Adults and children non-fatal cardiovascular serious adverse events,
Outcome 1 Formoterol versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 14 Adults and children non-fatal cardiovascular serious adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Busse 2004 0/80 0/80 0.0 [ 0.0, 0.0 ]
Busse 2004 1/80 0/80 7.39 [ 0.15, 372.38 ]
Corren 2007 0/123 0/131 0.0 [ 0.0, 0.0 ]
FitzGerald 1999 0/89 0/91 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 0/91 0.0 [ 0.0, 0.0 ]
Molimard 2001 0/130 0/129 0.0 [ 0.0, 0.0 ]
Steffensen 1995 0/103 1/101 0.13 [ 0.00, 6.69 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Wolfe 2006 1/1054 1/514 0.46 [ 0.02, 8.77 ]
Subtotal (95% CI) 1791 1258 0.69 [ 0.09, 5.21 ]
Total events: 2 (Formoterol), 2 (Control)
Heterogeneity: Chi2 = 2.16, df = 2 (P = 0.34); I2 =7%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Formoterol versus salbutamol
Busse 2004 0/80 0/79 0.0 [ 0.0, 0.0 ]
FitzGerald 1999 0/89 1/91 0.14 [ 0.00, 6.97 ]
LaForce 2005 0/86 2/88 0.14 [ 0.01, 2.21 ]
Steffensen 1995 0/103 0/100 0.0 [ 0.0, 0.0 ]
van Schayck 2002 0/46 0/41 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 404 399 0.14 [ 0.01, 1.33 ]
Total events: 0 (Formoterol), 3 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
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Analysis 15.1. Comparison 15 Impact of inhaled corticosteroids on asthma-related SAEs, Outcome 1
Patients with at least one asthma-related SAE.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 15 Impact of inhaled corticosteroids on asthma-related SAEs
Outcome: 1 Patients with at least one asthma-related SAE
Study or subgroup Formoterol Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Patients taking inhaled corticosteroids (all doses of formoterol))
Novartis 2005 26/2488 4/1319 100.0 % 2.58 [ 1.21, 5.49 ]
Subtotal (95% CI) 2488 1319 100.0 % 2.58 [ 1.21, 5.49 ]
Total events: 26 (Formoterol), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
2 Patients not taking inhaled corticosteroids (all doses of formoterol)
Novartis 2005 17/1280 1/544 100.0 % 3.22 [ 1.17, 8.89 ]
Subtotal (95% CI) 1280 544 100.0 % 3.22 [ 1.17, 8.89 ]
Total events: 17 (Formoterol), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
3 Patients taking inhaled corticosteroids (formoterol 12 mcg twice daily)
Novartis 2005 13/1389 4/1319 100.0 % 2.76 [ 1.06, 7.15 ]
Subtotal (95% CI) 1389 1319 100.0 % 2.76 [ 1.06, 7.15 ]
Total events: 13 (Formoterol), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.037)
4 Patients not taking inhaled corticosteroids (formoterol 12 mcg twice daily)
Novartis 2005 5/559 1/544 100.0 % 3.71 [ 0.75, 18.48 ]
Subtotal (95% CI) 559 544 100.0 % 3.71 [ 0.75, 18.48 ]
Total events: 5 (Formoterol), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
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Analysis 16.1. Comparison 16 Adults and children published non-fatal serious adverse events, Outcome 1
Formoterol versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 16 Adults and children published non-fatal serious adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2002 21/342 3/176 2.72 [ 1.15, 6.46 ]
Busse 2004 2/80 0/80 7.48 [ 0.46, 120.69 ]
Corren 2007 0/114 1/122 0.14 [ 0.00, 7.30 ]
LaForce 2005 1/86 0/91 7.83 [ 0.16, 395.30 ]
Levy 2005 1/127 0/122 7.10 [ 0.14, 358.29 ]
Steffensen 1995 0/103 2/101 0.13 [ 0.01, 2.11 ]
Von Berg 2003 6/164 1/84 2.45 [ 0.50, 11.95 ]
Subtotal (95% CI) 1016 776 2.31 [ 1.17, 4.53 ]
Total events: 31 (Formoterol), 7 (Control)
Heterogeneity: Chi2 = 7.53, df = 6 (P = 0.27); I2 =20%
Test for overall effect: Z = 2.43 (P = 0.015)
2 Formoterol versus salbutamol
Busse 2004 2/80 3/79 0.65 [ 0.11, 3.87 ]
LaForce 2005 1/86 2/88 0.52 [ 0.05, 5.08 ]
Steffensen 1995 0/103 0/100 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 269 267 0.60 [ 0.15, 2.44 ]
Total events: 3 (Formoterol), 5 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
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Analysis 17.1. Comparison 17 Adults and children all adverse events, Outcome 1 Formoterol versus
placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 17 Adults and children all adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2001 195/271 96/136 7.4 % 1.07 [ 0.68, 1.69 ]
Bensch 2002 293/342 151/176 5.7 % 0.99 [ 0.59, 1.66 ]
Busse 2004 43/80 48/80 3.9 % 0.78 [ 0.42, 1.45 ]
Corren 2007 67/123 77/131 6.2 % 0.84 [ 0.51, 1.38 ]
LaForce 2005 52/86 49/91 4.4 % 1.31 [ 0.72, 2.37 ]
Levy 2005 81/127 66/122 6.0 % 1.49 [ 0.90, 2.47 ]
Noonan 2006 77/123 54/125 6.2 % 2.17 [ 1.32, 3.57 ]
Pleskow 2003 183/275 95/141 8.3 % 0.96 [ 0.63, 1.48 ]
SD-037-0344 155/429 75/210 13.0 % 1.02 [ 0.72, 1.44 ]
Von Berg 2003 115/164 53/84 4.9 % 1.38 [ 0.79, 2.41 ]
Wolfe 2006 600/1054 285/514 34.0 % 1.06 [ 0.86, 1.31 ]
Subtotal (95% CI) 3074 1810 100.0 % 1.11 [ 0.98, 1.25 ]
Total events: 1861 (Formoterol), 1049 (Control)
Heterogeneity: Chi2 = 12.67, df = 10 (P = 0.24); I2 =21%
Test for overall effect: Z = 1.62 (P = 0.10)
2 Formoterol versus salbutamol
Bensch 2001 195/271 94/134 31.1 % 1.09 [ 0.69, 1.73 ]
Busse 2004 43/80 47/79 16.6 % 0.79 [ 0.42, 1.48 ]
LaForce 2005 52/86 49/88 18.0 % 1.22 [ 0.67, 2.22 ]
Pleskow 2003 183/275 96/138 34.2 % 0.87 [ 0.56, 1.35 ]
Subtotal (95% CI) 712 439 100.0 % 0.98 [ 0.76, 1.26 ]
Total events: 473 (Formoterol), 286 (Control)
Heterogeneity: Chi2 = 1.43, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
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Analysis 18.1. Comparison 18 Adults and children published adverse events, Outcome 1 Formoterol versus
placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 18 Adults and children published adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol versus placebo
Bensch 2001 195/271 96/136 10.0 % 1.07 [ 0.68, 1.68 ]
Bensch 2002 293/342 151/176 8.0 % 0.99 [ 0.59, 1.67 ]
Busse 2004 43/80 48/80 6.2 % 0.77 [ 0.41, 1.45 ]
LaForce 2005 52/86 49/91 5.3 % 1.31 [ 0.72, 2.38 ]
Levy 2005 81/127 66/122 6.8 % 1.49 [ 0.90, 2.48 ]
Pleskow 2003 183/275 95/141 11.7 % 0.96 [ 0.63, 1.48 ]
Von Berg 2003 115/164 53/84 5.9 % 1.37 [ 0.79, 2.39 ]
Wolfe 2006 600/1054 285/514 46.1 % 1.06 [ 0.86, 1.31 ]
Subtotal (95% CI) 2399 1344 100.0 % 1.09 [ 0.94, 1.26 ]
Total events: 1562 (Formoterol), 843 (Control)
Heterogeneity: Chi2 = 4.16, df = 7 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
2 Formoterol versus salbutamol
Bensch 2001 195/271 94/134 29.6 % 1.09 [ 0.69, 1.72 ]
Busse 2004 43/80 47/79 18.4 % 0.79 [ 0.42, 1.48 ]
LaForce 2005 52/86 49/88 16.1 % 1.22 [ 0.67, 2.22 ]
Pleskow 2003 183/275 96/138 35.9 % 0.87 [ 0.56, 1.35 ]
Subtotal (95% CI) 712 439 100.0 % 0.98 [ 0.76, 1.26 ]
Total events: 473 (Formoterol), 286 (Control)
Heterogeneity: Chi2 = 1.44, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
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Analysis 19.1. Comparison 19 Adults and children all published drug-related adverse events, Outcome 1
Formoterol versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 19 Adults and children all published drug-related adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Busse 2004 3/80 5/80 3.9 % 0.59 [ 0.14, 2.45 ]
FitzGerald 1999 13/89 9/91 10.0 % 1.55 [ 0.64, 3.77 ]
Steffensen 1995 33/103 38/101 23.9 % 0.78 [ 0.44, 1.39 ]
Wolfe 2006 121/1054 31/514 62.2 % 1.86 [ 1.30, 2.66 ]
Subtotal (95% CI) 1326 786 100.0 % 1.42 [ 1.07, 1.88 ]
Total events: 170 (Formoterol), 83 (Control)
Heterogeneity: Chi2 = 7.85, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 2.45 (P = 0.014)
2 Formoterol versus salbutamol
Busse 2004 3/80 3/79 7.7 % 0.99 [ 0.19, 5.02 ]
FitzGerald 1999 13/89 11/91 27.9 % 1.24 [ 0.53, 2.93 ]
Steffensen 1995 33/103 45/100 64.4 % 0.58 [ 0.33, 1.02 ]
Subtotal (95% CI) 272 270 100.0 % 0.75 [ 0.48, 1.18 ]
Total events: 49 (Formoterol), 59 (Control)
Heterogeneity: Chi2 = 2.24, df = 2 (P = 0.33); I2 =11%
Test for overall effect: Z = 1.26 (P = 0.21)
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Analysis 20.1. Comparison 20 Adults and children serious drug-related adverse events, Outcome 1
Formoterol versus placebo or salbutamol.
Review: Regular treatment with formoterol for chronic asthma: serious adverse events
Comparison: 20 Adults and children serious drug-related adverse events
Outcome: 1 Formoterol versus placebo or salbutamol
Study or subgroup Formoterol Control
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol versus placebo
Busse 2004 0/80 0/80 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 0/91 0.0 [ 0.0, 0.0 ]
Levy 2005 0/127 0/122 0.0 [ 0.0, 0.0 ]
Molimard 2001 0/130 0/129 0.0 [ 0.0, 0.0 ]
Pleskow 2003 1/275 0/141 4.54 [ 0.07, 285.25 ]
van der Molen 1997 0/125 0/114 0.0 [ 0.0, 0.0 ]
Von Berg 2003 0/164 0/84 0.0 [ 0.0, 0.0 ]
Wolfe 2006 2/1054 0/514 4.43 [ 0.23, 84.94 ]
Zimmerman 2004 0/201 1/101 0.05 [ 0.00, 3.20 ]
Subtotal (95% CI) 2242 1376 1.45 [ 0.18, 11.61 ]
Total events: 3 (Formoterol), 1 (Control)
Heterogeneity: Chi2 = 3.36, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.35 (P = 0.73)
2 Formoterol versus salbutamol
Busse 2004 0/80 0/79 0.0 [ 0.0, 0.0 ]
LaForce 2005 0/86 1/88 0.14 [ 0.00, 6.98 ]
Pleskow 2003 1/275 0/138 4.49 [ 0.07, 286.29 ]
Subtotal (95% CI) 441 305 0.71 [ 0.04, 12.34 ]
Total events: 1 (Formoterol), 1 (Control)
Heterogeneity: Chi2 = 1.42, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.23 (P = 0.82)
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A D D I T I O N A L T A B L E S
Table 1. Study sponsors
Study ID Sponsor
Bensch 2001 Novartis
Bensch 2002 Novartis
Busse 2004 Novartis
Corren 2007 AstraZeneca
Ekstrom 1998 AstraZeneca
Ekstrom 1998a AstraZeneca
FitzGerald 1999 Novartis
Hekking 1990 Not reported
Kesten 1991 Novartis
Kozlik-Feldmann 1996 Not reported
LaForce 2005 Novartis
Levy 2005 Novartis
Molimard 2001 Novartis
Noonan 2006 AstraZeneca
Pleskow 2003 Novartis
SD-037-0344 AstraZeneca
Steffensen 1995 Novartis
van der Molen 1997 AstraZeneca
van Schayck 2002 Not reported
Von Berg 2003 AstraZeneca
Wolfe 2006 Novartis
Zimmerman 2004 AstraZeneca
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Table 2. Proportion of participants using inhaled corticosteroids (ICS)
Study ID Proportion of participants on ICS
Bensch 2001 51%
Bensch 2002 69%
Busse 2004 64%
Corren 2007 0% (withdrawn)
Ekstrom 1998 86%
Ekstrom 1998a 89%
FitzGerald 1999 100%
Hekking 1990 Not reported
Kesten 1991 62%
Kozlik-Feldmann 1996 0%
LaForce 2005 67%
Levy 2005 72%
Molimard 2001 100%
Noonan 2006 100%
Pleskow 2003 44%
SD-037-0344 100%
Steffensen 1995 87%
van der Molen 1997 100%
van Schayck 2002 95%
Von Berg 2003 82%
Wolfe 2006 62%
Zimmerman 2004 100%
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Table 3. Intrinsic efficacy of beta-agonists
Drug Intrinsic efficacy (%)
Isoprenaline, adrenaline 100
Fenoterol 42
Formoterol 20
Salbutamol 4.9
Salmeterol < 2
Adapted fromHanania 2002. The authors acknowledge that it is difficult to determine the intrinsic efficacy of salmeterol given its high
lipophilicity.
A P P E N D I C E S
Appendix 1. Pharmacology of beta2-agonists
Beta2-agonists are thought to cause bronchodilation primarily through binding beta2-adrenoceptors on airways smooth muscle (ASM),
with subsequent activation of both membrane-bound potassium channels and a signalling cascade involving enzyme activation and
changes in intracellular calcium levels following a rise in cyclic adenosine monophosphate (cAMP) (Barnes 1993). However, beta2-
adrenoceptors are also expressed on a wide range of cell types where beta2-agonists may have a clinically significant effect including
airway epithelium (Morrison 1993), mast cells, post capillary venules, sensory and cholinergic nerves and dendritic cells (Anderson
2006). Beta2-agonists will also cross-react to some extent with other beta-adrenoceptors including beta1-adrenoceptors on the heart.
The in vivo effect of any beta2-agonist will depend on a number of factors relating to both the drug and the patient. The degree to
which a drug binds to one receptor over another is known as selectivity, which can be defined as absolute binding ratios to different
receptors in vitro, whilst functional selectivity is measured from downstream effects of drugs in different tissue types in vitro or in vivo.
All of the beta2-agonists described thus far are more beta2 selective than their predecessor isoprenaline in vitro. However, because
attempts to differentiate selectivity between the newer agents are confounded by so many factors, it is difficult to draw conclusions
about in vitro selectivity studies and probably best to concentrate on specific adverse side effects in human subjects at doses which
cause the same degree of bronchodilatation. The potency of a drug refers to the concentration that achieves half the maximal receptor
activation of which that drug is capable but it is not very important clinically as for each drug, manufacturers will alter the dose to try
to achieve a therapeutic ratio of desired to undesired effects. In contrast efficacy refers to the ability of a drug to activate its receptor
independent of drug concentration. Drugs that fully activate a receptor are known as full agonists and those that partially activate a
receptor are known as partial agonists. Efficacy also is very much dependent on the system in which it is being tested and is affected
by factors including the number of receptors available and the presence of other agonists and antagonists. Thus whilst salmeterol acts
as a partial agonist in vitro it causes a similar degree of bronchodilation to the strong agonist formoterol in stable asthmatic patients
(Van Noord 1996), presumably because there are an abundance of well-coupled beta2-adrenoceptors available with few downstream
antagonising signals. In contrast, with repetitive dosing formoterol is significantly better than salmeterol at preventing methacholine-
induced bronchoconstriction (Palmqvist 1999). These differences have led to attempts to define the ’intrinsic efficacy’ of a drug
independent of tissue conditions (Hanania 2002), as shown in Table 3. The clinical significance of intrinsic efficacy remains unclear.
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Appendix 2. Possible mechanisms of increased asthma mortality with beta-agonists
Direct toxicity
This hypothesis states that direct adverse effects of beta2-agonists are responsible for an associated increase inmortality andmost research
in the area has concentrated on effects detrimental to the heart. Whilst it is often assumed that cardiac side effects of beta2-agonists
are due to cross-reactivity with beta1-adrenoceptors (i.e. poor selectivity), it is worth noting that human myocardium also contains
an abundance of beta2-adrenoceptors capable of triggering positive chronotropic and inotropic responses (Lipworth 1992). Indeed,
there is good evidence that cardiovascular side effects of isoprenaline (Arnold 1985) and other beta2-agonists including salbutamol
(Hall 1989) are mediated predominantly via cardiac beta2-adrenoceptors thus making the concept of in vitro selectivity less relevant.
Generalised beta2-adrenoceptor activation can also cause hypokalaemia (Brown 1983) and it has been proposed that, through these
and other actions, beta2-agonists may predispose to life-threatening dysrhythmias or cause other adverse cardiac effects.
During the 1960s epidemic most deaths occurred in patients with severe asthma and it was originally assumed that asthma and its
sequelae, including hypoxia, were the primary cause of death. However, mucus plugging and hypoxia does not preclude a cardiac event
as the final cause of death, and one might expect those with severe asthma to take more doses of a prescribed inhaler. As noted by Speizer
and Doll most deaths in the 1960s were in the 10 to 19 age group and “at these ages children have begun to act independently and
may be particularly prone to misuse a self-administered form of treatment” (Speizer 1968). If toxicity were related to increasing doses
of beta2-agonists one might expect most deaths to occur in hospital where high doses are typically used and this was not the case. One
possible explanation for this anomaly was provided by animal experiments in which large doses of isoprenaline caused little ill effect in
anaesthetised dogs with normal arterial oxygenation whereas much smaller doses caused fatal cardiac depression and asystole (although
no obvious dysrhythmia) when hypoxic (Collins 1969; McDevitt 1974). It has been hypothesised therefore that such events would be
less likely in hospital where supplemental oxygen is routinely given. The clinical relevance of these studies remains unclear although
there is some evidence of a synergistic effect between hypoxia and salbutamol use in asthmatic patients in reducing total peripheral
vascular resistance (Burggraaf 2001) - another beta2-mediated effect which could be detrimental to the heart during an acute asthma
attack through a reduction in diastolic blood pressure. Other potential mechanisms of isoprenaline toxicity include a potential increase
in mucous plugging and worsening of ventilation perfusion mismatch despite bronchodilation (Pearce 1990).
Further concerns about a possible toxic effect of beta2-agonists were raised during the New Zealand epidemic in the 1970s. In 1981
Wilson et al, who first reported the epidemic, reviewed 22 fatal cases of asthma and noted “In 16 patients death was seen to be sudden
and unexpected. Although all were experiencing respiratory distress, most were not cyanosed and the precipitate nature of their death
suggested a cardiac event, such as an arrest, inappropriate to the severity of their respiratory problem” (Wilson 1981). In humans,
fenoterol causes significantly greater chronotropic, inotropic and electrocardiographic side effects than salbutamol in asthmatic patients
(Wong 1990). Interestingly, across the same parameters fenoterol also causes more side effects than isoprenaline (Burgess 1991).
In patients with mild asthma and without a bronchoconstrictor challenge, salmeterol and salbutamol cause a similar degree of near
maximal bronchodilation at low doses (Bennett 1994). However, whilst as a one-off dose salbutamol is typically used at two to four
times the concentration of salmeterol, the dose equivalences for salmeterol versus salbutamol in increasing heart rate and decreasing
potassium concentration and diastolic blood pressure were 17.7, 7.8 and 7.6 respectively (i.e. salmeterol had a greater effect across
all parameters). Given the lower intrinsic efficacy of salmeterol (Table 1), these results highlight the importance of in vivo factors;
one possible explanation for the difference is the increased lipophilicity of salmeterol compared to salbutamol contributing to higher
systemic absorption (Bennett 1994).
When comparing increasing actuations of standard doses of formoterol and salmeterol inhalers in stable asthmatic patients, relatively
similar cardiovascular effects are seen at lower doses (Guhan 2000). However, at the highest doses (above those recommended by
the manufacturers) there were trends towards an increase in systolic blood pressure with formoterol; in comparison there was a trend
towards a decrease in diastolic blood pressure and an increase in QTc interval with salmeterol although no statistical analysis of the
difference was performed. In contrast in asthmatic patients with methacholine-induced bronchoconstriction there was no significant
difference between salmeterol and formoterol in causing increased heart rate and QTc interval although formoterol caused significantly
greater bronchodilation and hypokalaemia (Palmqvist 1999). Whilst there is good evidence of cardiovascular and metabolic side effects
with increasing doses of beta2-agonists, it is a little difficult to envisage serious adverse effects of this nature when using LABAs at
manufacturer-recommended preventative doses. However, it is possible that some patients choose to use repeated doses of LABAs
during exacerbations.
Tolerance
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In this setting, the term tolerance refers to an impaired response to beta2-agonists in patients who have been using regular beta2-
agonist treatment previously (Haney 2006). Tolerance is likely to result from a combination of reduced receptor numbers secondary to
receptor internalisation and reduced production and also uncoupling of receptors to downstream signalling pathways following repeated
activation (Barnes 1995). This phenomenon is likely to explain the beneficial reduction in systemic side effects seen with regular use of
beta2-agonists including salbutamol after one to two weeks (Lipworth 1989). However, the same effect on beta2-adrenoceptors in the
lung might be expected to produce a diminished response to the bronchodilating activity of beta2-agonists following regular use. In
patients with stable asthma, whilst there is some evidence of tolerance to both salbutamol (Nelson 1977) and terbutaline (Weber 1982)
other studies have been less conclusive (Harvey 1982; Lipworth 1989). However, evidence of tolerance to short and long-acting beta2-
agonists in both protecting against and reducing bronchoconstriction is much stronger in the setting of an acute bronchoconstrictor
challenge with chemical, allergen and ’natural’ stimuli (Haney 2006; Lipworth 1997).
Studies comparing salmeterol and formoterol have shown that both cause tolerance compared to placebo but there was no significant
difference between the drugs (van der Woude 2001). There also appears to be little difference in the tolerance induced by regular
formoterol and regular salbutamol treatment (Hancox 1999; Jones 2001). To the authors’ knowledge no studies have looked specifically
at the degree of tolerance caused by isoprenaline and fenoterol in the setting of acute bronchoconstriction. Tolerance to bronchodilation
has been shown to clearly occur with addition of inhaled corticosteroids to salmeterol and formoterol (Lee 2003) and terbutaline (Yates
1996). There is conflicting evidence as to whether high-dose steroids can reverse tolerance in the acute setting (Jones 2001; Lipworth
2000).
At first glance the toxicity and tolerance hypothesesmight appear incompatible as systemic and cardiovascular tolerance ought to protect
against toxicity in the acute setting and there is good evidence that such tolerance occurs in stable asthmatic patients (Lipworth 1989).
However, whilst this study showed that changes in heart rate and potassium levels were blunted by previous beta2-agonist use, they
were not abolished; furthermore, at the doses studied these side effects appear to follow an exponential pattern (Lipworth 1989). In
contrast, in the presence of bronchoconstrictor stimuli the bronchodilator response to beta2-agonists follows a flatter curve (Hancox
1999; Wong 1990) and as previously discussed this curve is shifted downwards by previous beta2-agonist exposure (Hancox 1999).
Thus, it is theoretically possible that in the setting of an acute asthmatic attack and strong bronchoconstricting stimuli, bronchodilator
tolerance could lead to repetitive beta2-agonist use and ultimately more systemic side effects than would otherwise have occurred. Of
course, other sequelae of inadequate bronchodilation including airway obstruction will be detrimental in this setting.
Whilst the tolerance hypothesis is often cited as contributing towards the asthma mortality epidemics it is difficult to argue that
reduced efficacy of a drug can cause increased mortality relative to a time when that drug was not used at all. However, tolerance
to the bronchodilating effect of endogenous circulating adrenaline is theoretically possible and there is also evidence of rebound
bronchoconstriction when stopping fenoterol (Sears 1990), which may be detrimental. Furthermore, it appears that regular salbutamol
treatment can actually increase airway responsiveness to allergen (Cockcroft 1993) a potentially important effect that could form a
variant of the toxicity hypothesis. Differences between beta2-agonists in this regard are unclear, but the combination of rebound hyper
responsiveness and tolerance of the bronchodilator effect with regular beta2-agonist exposure has been recently advocated as a possible
mechanism to explain the association between beta2-agonists and asthma mortality (Hancox 2006).
Other explanations
Confounding by severity
Historically, this hypothesis has been used extensively to try to explain the association between mortality and the use of fenoterol during
the 1970s New Zealand epidemic (see Pearce 2007) and is still quoted today. The hypothesis essentially relies on the supposition that
patients with more severe asthma are more likely to take either higher doses of beta2-agonists or a particular beta2-agonist (such as
fenoterol) thereby explaining the association. This hypothesis was carefully ruled out in the three case-control studies by comparing
the association between fenoterol and mortality in patients with varying severity of disease (Crane 1989; Grainger 1991; Pearce 1990).
Furthermore, the hypothesis cannot explain the overall increase in mortality in the 1960s and 1970s nor can it explain any significant
increase in mortality (whether taking inhaled steroids or not) from randomised controlled trial data.
The delay hypothesis
This hypothesis accepts that beta2-agonists or a particular beta2-agonist cause an increased risk of mortality but indirectly by causing
patients to delay before getting medical help and further treatments including high dose steroids and oxygen. There is evidence that
both salmeterol and formoterol can reduce awareness of worsening underlying inflammation (Bijl-Hofland 2001; McIvor 1998). It
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is difficult to rule out the delay hypothesis in either explaining or contributing towards both the asthma mortality epidemics and an
association with regular use of LABAs. There is evidence that beta2-agonists with higher intrinsic efficacy are more effective at relieving
bronchoconstriction in the acute setting (Hanania 2007) and could paradoxically cause patients to delay seekingmedical help for longer.
For the delay hypothesis to explain the increase in mortality during the 1960s and 1970s one has to imply that hospital treatment of
asthma when mortality rates were low during the earlier years of the 20th century was effective. It is difficult to say exactly how effective
such treatment is likely to have been.
Reduced corticosteroid treatment
A slight but significant variation of the delay hypothesis suggests that patients who have separate beta2-agonists and corticosteroid
inhalers may choose to take less corticosteroid because of better symptom control from the inhaled beta2-agonists and it is reduced
corticosteroid treatment that contributes to a rise in mortality. It is rather difficult to see how this hypothesis explains the epidemics of
asthma deaths in the 1960s and 1970s relative to the 1920s and 30s (Figure 1), given that corticosteroids were not used for the treatment
of asthma in the earlier decades. If this hypothesis were to explain increased mortality from more recent randomised controlled trial
data one would not expect to see an increase in mortality in those taking LABAs alone.
Appendix 3. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
CENTRAL (T he Cochrane Library) Quarterly
PSYCINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
101Regular treatment with formoterol for chronic asthma: serious adverse events (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
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7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
Appendix 4. Definition of serious adverse events
The Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH) define serious adverse events as follows (ICHE2a 1995):
“A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:
• Results in death,
• Is life-threatening,
• Requires inpatient hospitalisation or prolongation of existing hospitalisation,
• Results in persistent or significant disability/incapacity, or
• Is a congenital anomaly/birth defect.
NOTE: The term ”life-threatening“ in the definition of ”serious“ refers to an event in which the patient was at risk of death at the time
of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.”
WH A T ’ S N E W
Last assessed as up-to-date: 5 January 2012.
Date Event Description
5 January 2012 New search has been performed No new studies found. Minor edits made and plain lan-
guage summary revised
5 January 2012 New citation required but conclusions have not changed New search carried out in January 2012 but no new
studies included
H I S T O R Y
Protocol first published: Issue 1, 2008
Review first published: Issue 4, 2008
Date Event Description
10 November 2008 Amended The ’Summary of findings’ tables have been reordered. Contents are unchanged. An additional
reference has also been added for Corren 2007. The Primary Analysis has been changed to Peto
Odds Ratio.
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C O N T R I B U T I O N S O F A U T H O R S
CJC: conception of the idea, study selection and data collection, statistical analysis and co-writing of the review.
MJC: background information (including Appendices), study selection and co-writing of the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• NHS R&D, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not use risk difference as the primary metric for analysis of rare events, due to new advice in the latest revision of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2008). One of the peer reviewers also pointed out that Bradburn 2007 cautions
against the use of inverse-variance and DerSimonian and Laird methods for sparse data, so for the 2009 update we used the Peto OR
for the primary analysis, as no continuity correction is required for zero cells. This brings the analysis for this review in line with the
other reviews in this series.
Also we investigated reporting bias by comparing published and unpublished serious adverse events, and investigating the impact of
using drug-related adverse events and the combined results from serious and non-serious adverse events.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenergic beta-Agonists [∗adverse effects]; Age Factors; Albuterol [adverse effects]; Asthma [∗drug therapy; mortality]; Bronchodilator
Agents [∗adverse effects]; Chronic Disease; Ethanolamines [∗adverse effects]
MeSH check words
Adult; Child; Humans
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